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ABSTRACT 
Kathryn Connell Gersh 
Recombinant γ′ Fibrinogen and its Interaction with Factor XIII 
(Under the direction of Susan T. Lord) 
 
 Because the γ′ chain of fibrinogen has been hypothesized as a binding site for 
factor XIII zymogen, I prepared two recombinant fibrinogen variants, a γ′/γ′ fibrinogen 
homodimer and a γ/γ′ fibrinogen heterodimer.  Characterization of their expression in 
CHO cells revealed the following:  1) γ′ chain protein is produced in about the same 
proportion as γ′ mRNA in any given cell line.  2) γ and γ′ chains assemble into 
homodimeric fibrinogen molecules as readily as they do heterodimers.  3) Mass 
spectrometry studies indicate that one of two tyrosine residues in the recombinant γ′ chain 
is sulfated.   
I next characterized the polymerization of purified recombinant γ′/γ′ and γ/γ′ 
fibrinogen.  As measured by turbidity, the presence of the γ′ chain leads to decreased 
lateral aggregation at all calcium concentrations studied.  I monitored fibrinopeptide 
release by HPLC and found that release of fibrinopeptide A occurs at the same rate 
regardless of the presence of a γ′ chain, but fibrinopeptide B release is faster from γ′/γ′ 
than γ/γ or γ/γ′ fibrinogen.   Factor XIIIa-catalyzed cross-linking of the variants starts at a 
slower rate for fibrinogens with a γ′ chain than it does for those without. 
 iv 
 I then used the γ′/γ′ and γ/γ′ fibrinogen variants in an ELISA assay to measure 
factor XIII binding to fibrinogen and fibrin.  I studied binding of factor XIII zymogen, 
recombinant factor XIII composed of just A subunits, and active-site-inhibited, activated 
recombinant factor XIIIa.  No matter what form the factor XIII is in, or whether fibrinogen 
or fibrin is used, these experiments clearly showed that the γ′ chain has no role in factor 
XIII binding to fibrinogen.   
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CHAPTER ONE 
 
 
INTRODUCTION 
 2 
            Upon blood vessel injury, endothelium ruptures and exposes the membrane protein 
tissue factor to blood from within the vessel.  Tissue factor forms a complex with factor VIIa 
that catalyzes the activation of factor IX into IXa and factor X into Xa [1].  On the surface of 
the tissue-factor bearing cell, Xa participates with Va in formation of a prothrombinase 
complex to convert prothrombin to thrombin on a small scale.  This thrombin then converts 
XI to XIa, dissociates the VIII/von Willebrand factor complex to activate VIIIa, converts V 
to Va, and activates platelets [2]. 
IXa that has been activated by the TF:VIIa complex dissociates from the surface of 
the tissue-factor bearing cell, travels through the blood, and binds to negatively-charged 
phospholipids on the surface of the activated platelet.  It then forms the tenase complex with 
VIIIa to convert larger quantities of X to Xa on the platelet surface.  In turn, Xa complexes 
with Va to form the prothrombinase complex that generates large quantities of active 
thrombin on the platelet surface [2].  This thrombin then converts fibrinogen to fibrin to form 
a clot; it also converts factor XIII to active factor XIIIa.  Factor XIIIa covalently cross-links 
fibrin fibers to mechanically stabilize the clot.  It is these last two steps of the coagulation 
pathway, fibrin formation and cross-linking by factor XIIIa that are the subject of my studies. 
 
Fibrinogen 
 The fibrin clot’s precursor is the protein fibrinogen, a 340 kDa glycoprotein.  Human 
plasma fibrinogen is synthesized in the liver at a rate of 1.7 – 5.0 g per day and circulates at a 
concentration of approximately 2.5 mg/mL [3].  Fibrinogen is composed of two copies of 
each of three polypeptide chains, termed the Aα chain (66.5 kDa), the Bβ chain (52 kDa), 
and the γ chain (46.5 kDa).  Alternative splicing of the γ chain mRNA leads to an extended γ 
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chain termed the γ′ chain, present in about 10% of plasma fibrinogen molecules.  This chain 
has a molecular weight of 51.5 kDa due to the replacement of the last four amino acids of the 
γ chain (Ala – Gly – Asp – Val) with a negatively charged 20 amino acid residue sequence 
[4].  This replacement results from translation of the last intron up to a stop codon, 
eliminating translation of the final exon [5].  Due to the high density of negatively charged 
residues on the γ′ chain, this polypeptide chain has significantly different biochemical 
characteristics than does the normally spliced γ chain. 
 An early observation of fibrinogen by electron microscopy suggested a tridodular 
model [6].  A more complete picture of the molecule’s three-dimensional structure was 
determined by a combination of electron microscopy and low resolution X-ray 
crystallography [7].  Fibrinogen has a rod-like structure with the N-termini of all six chains 
held together by disulfide bonds in the center of the molecule in a region known as the E 
region.  The chains extend out from this region as half-molecules, first forming two coiled-
coils.  At the end of each coiled-coil the C-termini of the more mobile Aα chains double 
back onto the coiled-coil.  The C-termini of the Bβ and γ chains, however, each form 
individual globular domains that compose the D regions at each end of the molecule [7]. 
 Later, low resolution structures were determined by X-ray crystallography for bovine 
and chicken fibrinogen [8], [9].  Crystallization of the entire human fibrinogen molecule is 
difficult due to the mobility of the C-termini of the Aα chains (termed the αC regions).  
However, crystal structures of D fragments isolated from both plasma and recombinant 
fibrinogen have recently been published [10], [11]. 
 Conversion of fibrinogen into fibrin occurs when thrombin cleaves fibrinopeptides 
from the N-termini of the Aα and Bβ chains of fibrinogen to expose polymerization sites A 
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and B, respectively.  Once exposed, these polymerization sites are capable of interaction with 
the constitutively available a and b polymerization sites in the D region of another 
fibrin(ogen) molecule.  These results were determined by affinity chromatography of 
fibrin(ogen) fragments over a column composed of fibrinogen and fibrin monomers coupled 
to sepharose [12].  The a site is a pocket located at the C-terminus of the γ chain while the b 
site pocket is located at the C-terminus of the (B)β chain [13],[14].  A-a interactions between 
fibrin monomers lead to formation of a double-stranded, half-staggered protofibril, as 
deomonstrated by electron micrographs of fibrin trimers [15].  Further studies with high 
resolution electron micrographs demonstrate that protofibrils exist as twisted structures [16].  
Light scattering experiments performed to study the kinetics of clot formation suggest that 
once protofibrils have grown to an appropriate length they laterally aggregate.  Lateral 
aggregation requires preformed protofibrils because the individual interactions involved are 
weak on their own, but become significant as protofibrils become longer.  During this 
process, longer protofibrils branch out as well as laterally aggregate with two protofibrils, 
and the network of fibers that composes a clot will form [17].  The results of the light 
scattering experiments from which this model was proposed were confirmed by electron 
microscopy [18].  Finally, the noncovalent clot is stabilized by factor XIIIa-catalyzed 
covalent cross-linking [19].   
 The process of clot formation follows strict kinetics.  HPLC was used to measure the 
release of fibrinopeptides from bovine fibrinogen.  This study showed that fibrinopeptide A 
(FpA) is released first while fibrinopeptide B (FpB) release is very slow at the start of the 
reaction, but speeds up after FpA release is complete [20].  Experiments with mutant 
fibrinogen Detroit, from which FpA is not cleaved, confirm that cleavage of FpA is required 
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for efficient FpB cleavage [21].  Fibrinopeptides were released at an equal rate from a 
recombinant fibrinogen in which the FpB sequence was replaced by sequence for FpA, 
showing that the difference in kinetics between FpA and FpB release is due to thrombin’s 
specificity for the sequence of the fibrinopeptide [22]. Conversion of fibrinogen to fibrin at 
neutral pH leads to dissociation of the αC domains from the center part of the molecule, as 
demonstrated by electron microscopy comparisons of fibrinogen and fibrin monomer.  Other 
experiments in this same study showed the interaction of αC fragments with one another, 
suggesting the possibility that they may be involved with intermolecular interactions in vivo 
[23].  These domains are hypothesized to be involved with lateral aggregation, according to 
one model of fibrin polymerization.  Electron microscopy and turbidity studies of fibrinogen 
fragment X, from which the αC domains are removed, form clots with altered ability to 
laterally aggregate [24]. 
 
Factor XIII 
 Factor XIIIa catalyzes the formation of Nε(γ-glutamyl)lysine cross-links between two 
γ chains, multiple α chains, or a γ and an α chain of neighboring fibrin molecules within the 
clot.  The plasma-derived form of this enzyme is composed of two A and two B subunits 
[25].  Plasma factor XIII has a molecular weight of 325.8 kDa; the A subunit weighs 83.2 
kDa while the B subunit weighs 79.7 kDa.  These subunits noncovalently associate into a 
tetramer [26].  A combination of ELISA assays showed that the plasma concentration of B 
subunits was 0.26 - 0.28 µmol/L while the concentration of A subunits was 0.13 – 0.16 
µmol/L.  These ELISA assays also indicated that all of the A subunits in plasma were 
complexed with B subunits while half of the B subunits existed free in solution [27].  In 
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addition to the plasma form of the enzyme, platelet factor XIII exists as an A2 dimer with no 
B subunits.  These two forms of the enzyme have an equal share of total factor XIII activity 
in blood [28]. 
 Factor XIII’s active site is located within the A subunit.  The crystal structure of this 
subunit has been solved and shows the presence of a beta sandwich domain, the catalytic 
core, and two beta barrel domains [29].  The active site holds a catalytic triad of Cys314-
His373-Asp396.  Substrate access to this catalytic core is blocked by a 37-residue activation 
peptide located at the N-terminus of the A-chain.   The two A subunits of the molecule 
associate as a dimer with the activation peptide from one subunit blocking access to the other 
subunit’s active site [29]. 
 Unlike the A subunits of factor XIII, factor XIII B subunits have not been crystallized 
so much less is known regarding their structure.  While the hydrophobic A subunit is 
carbohydrate-free, the B subunit is highly glycosylated [25].  B subunits act as regulatory and 
carrier subunits for the A subunits as they travel through the plasma [30].  
Activation of plasma factor XIII is a multistep process.  This process is initiated by 
thrombin-catalyzed cleavage of the activation peptide [31].  Even though there are two active 
sites present per factor XIII molecule, only one activation peptide must be cleaved for full 
factor XIIIa activity, as demonstrated by the incorporation of only one equivalent of 
iodoacetamide into the active site of each molecule [32].  Crystallographic evidence suggests 
that after cleavage this peptide may not immediately dissociate from its native position and 
conformation because the activation peptide is still in place in the crystal structure of 
thrombin-cleaved factor XIII A2 dimer [33].  The next step in activation involves dissociation 
of the carrier B subunits from the A2 dimer, and the process of factor XIIIa generation is 
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completed when the A2 dimer presents the active site cysteine residue, presumably through a 
conformational change [34].  Because the thrombin-cleaved form of the molecule did not 
crystallize in the active conformation, the exact structural changes necessary to produce this 
state are still a matter of speculation [33].  However, the crystal structure of the inactive 
molecule suggests that in the presence of calcium, one or both of the beta barrel domains 
would move to provide access to the active site [29]. 
 This activation process requires two cofactors.  The first of these cofactors is calcium.  
Calcium is required to be present for conversion of proteolytically cleaved factor XIII 
(FXIII′) to active factor XIII (FXIIIa).  The concentration of calcium required for 50% 
conversion at physiological pH and ionic strength was determined to be 25 mM by [14C]-
iodoacetamide incorporation [34].  It has been suggested that in vivo, calcium acts as an 
allosteric effector to cause dissociation of the B subunits and/or the conformational change in 
the A2 dimer that exposes the active site [35]. 
 The other important cofactor in thrombin-catalyzed factor XIII activation is 
fibrin(ogen).  Fibrinogen has been shown to lower to physiological levels the concentration 
of calcium required for factor XIIIa generation, as determined by incorporation of 
iodoacetamide into the active site of the molecule [36].  The formation of a complex between 
thrombin, factor XIII A2B2, and des A,B-fibrin led to a 100-fold increase in the factor XIIIa 
activity in a [3H]-putrescine incorporation assay compared to thrombin and factor XIII alone.  
Factor XIIIa generation from platelet factor XIII that lacked B subunits required 50% less 
thrombin than did factor XIII zymogen, but this thrombin requirement moved to the level of 
plasma factor XIII when platelet factor XIII was incubated with pure B subunits.  Addition of 
fibrin to the mixture of platelet A2B2 factor XIII and thrombin produced factor XIIIa activity 
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equal to A2 platelet factor XIII and thrombin alone.  These results suggest that fibrin can 
remove the inhibitory effect of B subunits from factor XIIIa generation [37].  Kinetic HPLC 
studies of fibrinopeptide and activation peptide release showed that inclusion of fibrinogen 
with thrombin and factor XIII provided an approximately 35-fold increase in the rate of 
activation peptide release [38].  Fibrin-catalyzed promotion of activity keeps factor XIII from 
becoming active before substrate is available.  The cofactor role of fibrin serves to regulate 
factor XIIIa activity to just those times when it can be useful [39].   Figure 1.1 shows the 
steps of factor XIII activation and necessary cofactors. 
Once activated, factor XIII is ready to catalyze a transglutaminase reaction.  The 
active site cysteine of factor XIII forms a thioester bond with a glutamine side chain located 
on the protein substrate (generally fibrin) [30].  Next the enzyme-substrate complex binds to 
the side chain of a lysine residue on another protein molecule, as shown by the inhibition of 
cross-linking by a synthetic lysine methyl ester [40].  A rearrangement quickly takes place 
liberating the enzyme and creating an isopeptide bond between the two proteins [41].  See 
Figure 1.2. 
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Figure 1.1.  Activation of factor XIII is a three-step process that requires thrombin for 
initiation as well as fibrin(ogen) and calcium as cofactors. 
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Figure 1.2.  Transglutaminase reaction catalyzed by factor XIIIa.  In this case, two molecules 
of fibrin are being cross-linked. 
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 During fibrin clot formation, the transglutaminase reaction first takes place between γ 
chains of fibrin.  Between each set of two aligned fibrin molecules, two cross-links can form.  
The glutamine acceptors are Gln 398 or Gln 399; the lysine donor on each molecule is Lys 
406.  Two cross-links can form between each pair of D regions; from the lysine on each 
molecule to either of the glutamines on the other [42], [43].  The orientation of these cross-
links within the protofibril has been a subject of recent debate.  Some put forth an argument 
that cross-links are situated transversely between fibrin molecules on two adjacent fibrin 
molecules [44].  A more widely accepted model based on structural evidence obtained from 
crystallography and electron microscopy suggests that these cross-links are formed 
longitudinally between fibrin molecules aligned end-to-end [45]. 
 After γ-γ dimer formation has begun to occur, cross-links between α chains of fibrin 
start to form.  Four glutamine acceptors are available on the α chain for cross-link formation 
(Gln 221, Gln 237, Gln 328, and Gln 366) along with a host of lysine donors.  Unlike with γ 
chains, this availability leads to the formation of cross-linked α polymers, rather than just 
dimers [46], [47], [48], [49]. 
 In addition to the γ and α chains of fibrin, factor XIII is responsible for cross-linking 
many other proteins available in the blood.  It cross-links α2-antiplasmin to the α chain of 
fibrin to regulate plasmin-catalyzed fibrinolysis [50].  Another substrate for factor XIII is 
fibronectin which is cross-linked to fibrin during the process of wound healing.  Once 
attached to fibrin, fibronectin is further cross-linked to collagen to assist in clot attachment to 
the blood vessel wall [51]. 
 Factor XIII has also been shown through both in vitro and in vivo studies to play a 
role in up-regulating angiogenesis [52].  Factor XIII binds to the surface of an endothelial 
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cell and cross-links the integrin αVβ3 to vascular endothelial growth factor A (VEGF-A).  
This interaction then leads to a signaling cascade which eventually triggers cell proliferation 
and migration resulting in angiogenesis [53]. 
 
Fibrinogen and Factor XIII 
 Early efforts to purify factor XIII from plasma were complicated by the fact that 
factor XIII coprecipitates with fibrinogen and can only be separated by heat denaturation of 
the fibrinogen [54].  Greenberg and Shuman mixed radiolabeled factor XIII with fibrinogen 
immobilized on beads and discovered that plasma factor XIII does, indeed, bind to fibrinogen 
with a binding constant of 1.4 +/- 0.06 x 10-8M.  Addition of unlabeled platelet factor XIII to 
the 125I-plasma factor XIII / fibrinogen bead mixture could completely inhibit 125I-plasma 
factor XIII binding to fibrinogen, just as could unlabeled plasma factor XIII.  From this 
result, Greenberg and Shuman concluded that the fibrinogen binding site on factor XIII is 
located on the A subunits [55].  In contrast, Hornyak and Shafer showed that radiolabeled 
factor XIII zymogen did not disrupt binding of radiolabeled, active-site blocked factor XIIIa 
to fibrin.  In their system, fibrinogen and blocked factor XIIIa were added to acid-solubilized 
fibrin that was then allowed to clot and spun down.  From these experiments, they concluded 
that the factor XIII zymogen / fibrinogen interaction is mediated through the B subunits [56]. 
 In 1996, Siebenlist and coworkers suspected that the γ′ chain of fibrinogen may play a 
role in binding to factor XIII zymogen.  They separated human plasma fibrinogen into a γ/γ 
fraction and a γ/γ′ fraction by ion-exchange chromatography.  Because they had previously 
observed factor XIII activity in the γ/γ′ fraction, they performed an ammonium sulfate 
precipitation on this fraction only.  γ/γ′ Fibrinogen containing factor XIII was precipitated, 
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while γ/γ′ fibrinogen without factor XIII remained soluble.  To perform their experiments, 
Siebenlist et al. mixed either γ/γ or γ/γ′ fibrinogen with factor XIII and analyzed binding by 
ion-exchange and size-exclusion chromatography.  When mixed with γ/γ′ fibrinogen and 
subjected to ion-exchange chromatography, factor XIII had a different elution position; this 
effect was not observed with γ/γ fibrinogen.  Size-exclusion chromatography also showed 
that factor XIII co-eluted with γ/γ′ fibrinogen, but not with γ/γ fibrinogen.  From these 
experiments, they concluded that the γ′ chain provides a binding site for factor XIII zymogen 
[57]. 
Localization of factor XIII on the γ′ chain of fibrinogen is supported by the observed 
resistance to lysis of fibrin clots composed of γ/γ′ fibrinogen compared with γ/γ clots.  Falls 
and Farrell purified γ/γ and γ/γ′ fibrinogen from plasma fibrinogen using much the same 
method as described above for Siebenlist, though notably, they omitted the ammonium 
sulfate fractionation to remove bound factor XIII.  They measured clot lysis by combining γ/γ 
or γ/γ′ fibrinogen with thrombin, tPA, and plasminogen in a microtiter plate and monitoring 
the formation and dissolution of the clot.  They discovered that γ/γ and γ/γ′ fibrin lyse at the 
same rate, but when factor XIII is added to the reaction, γ/γ′ fibrin lyses more slowly than γ/γ 
and results in more extensively cross-linked D-dimer lysis products.  They hypothesized that 
this difference in lysis is due to γ/γ′ fibrinogen binding factor XIII and localizing it to the clot 
[58]. 
Moaddel and coworkers extended the studies described above by measuring the 
strength of the factor XIII zymogen / fibrinogen interaction by sedimentation equilibrium 
analytical ultracentrifugation.  The affinity of factor XIII for γ/γ′ fibrinogen was 20 times 
stronger than factor XIII’s affinity for γ/γ fibrinogen.  The stoichiometry of the complexes 
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formed in the analytical ultracentrifuge was determined to be two fibrinogen molecules and 
one molecule of factor XIII.  One attractive possibility for how this complex forms may be 
envisioned as shown in Figure 1.3 [59].  
Activation of factor XIII leads to dissociation of the B subunits and therefore the loss 
of this proposed B:γ′ interaction.  Thus, active A subunits must bind elsewhere.  Procyk et al. 
examined the binding of active factor XIII to fibrinogen using recombinant factor XIII A 
subunits [60].  The recombinant A2 was radiolabeled with 125I, activated, and added to small 
columns containing fibrin clots.  The column was washed with buffer, and the total amount 
of radioactivity released from the clot was measured to determine the amount of factor XIII 
A2 bound to the clot.  Binding could be blocked by an antibody to the C-terminus of the Aα 
chain, suggesting that the binding site for factor XIIIa is located somewhere between residues 
389-402.  Unactivated recombinant factor XIII (A2) did not bind significantly to fibrin [60]. 
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Figure 1.3. Schematic diagram of how factor XIII may interact with fibrinogen.   Fibrinogen 
is shown in blue, while factor XIII is shown in red (B subunits) and orange (A subunits).  
This arrangement is one way in which the B subunits of one factor XIII molecule may 
simultaneously interact with two fibrinogen molecules.  Based on a figure by Moaddel et al. 
[59]. 
A A 
B 
Factor XIII 
Fibrinogen Fibrinogen 
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Summary of Dissertation Research 
While these experiments have provided initial information regarding the binding sites 
on fibrinogen for factor XIII, each has some drawbacks.  In the initial experiments suggesting 
the γ′ chain as a binding site for factor XIII [57], plasma fibrinogen was separated by ion-
exchange chromatography to yield the two populations γ/γ and γ/γ′.  While this method 
separates γ/γ′ from γ/γ based on their charge difference, another modification may be present 
elsewhere in the molecule that contributes to their separation.  Other changes to a fraction of 
the fibrinogen molecules such as glycosylation or post-translational modifications would 
have no relation to the γ′ chain, but could still affect charge and chromatographic separation.  
To confirm that the γ′ chain is indeed involved in binding to factor XIII, I have generated 
recombinant fibrinogen with a γ′ chain for use in binding studies.  I prepared two 
recombinant fibrinogen variants: one with γ′ chains on both ends of the molecule (γ′/γ′), and 
the other with one γ′ chain and one normally spliced γ chain (γ/γ′).  The γ/γ′ variant resembles 
the form in which the γ′ chain is found physiologically. 
While synthesizing the recombinant fibrinogen variants, I studied the expression of 
the γ and γ′ chains in CHO cells to determine if they are expressed with equal efficiency and 
whether γ/γ′ heterodimers form as easily as do homodimers.  I also compared the 
polymerization of γ/γ′ and γ′/γ′ fibrinogen compared to normal recombinant fibrinogen.  
Regarding the binding of factor XIII to fibrinogen, the Moaddel model derived from 
ultracentrifugation experiments is a useful starting point, but care must be taken in 
interpretation of these data.  This investigation has received some criticism regarding the 
possibility of factor XIII zymogen cross-linking fibrinogen during the extended 
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ultracentrifugation [61].  To account for these considerations, I performed binding studies 
using alternative methods such as ELISA. 
The binding studies included in this work are designed to determine whether or not 
the γ′ chain has a role in binding to factor XIII.  If the Moaddel model of two fibrinogen 
molecules interacting end to end with one factor XIII molecule holds true, then this variant 
provides a range of interaction sites for factor XIII: two γ chains, two γ′ chains, or one γ and 
one γ′ chain.  The γ′/γ′ variant does not exist at significant concentrations in human plasma, 
but provides an excellent positive control with only γ′ chains available for binding.  Factor 
XIII binding to these two molecules was compared with binding to normal recombinant 
fibrinogen that contains only γ chains.  My experiments also address the question of how this 
proposed binding site functions when factor XIII is in its zymogen form compared to its 
active form and were performed with factor XIII zymogen, recombinant factor XIII A2, and 
active-site inhibited recombinant factor XIIIai. 
Fibrinogen’s role as cofactor for factor XIII activation was also explored using my 
γ′/γ′ and γ/γ′ variants.  After exposure to variant cofactors, factor XIII activity was monitored 
by the extent of cross-link formation within each variant catalyzed by factor XIII activated in 
situ compared to pre-activated factor XIIIa.  In addition, I compared how the presence of 
factor XIII affects polymerization of the γ′/γ′ and γ/γ′ variants. 
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EXPRESSION OF γ′/γ′ AND γ/γ′ FIBRINOGEN IN CHO CELLS 
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Summary 
 Circulating fibrinogen is highly heterogeneous, with several sites of variability in 
each chain [1].  The γ/γ′ variant with one normally spliced γ chain and one γ′ chain is present 
in around 10% of fibrinogen molecules in a normal individual’s plasma [2].  The γ′/γ′ 
homodimer is much more rare physiologically. We prepared each of these recombinant 
fibrinogen variants and expressed them in CHO cells to provide material for studying the 
putative factor XIII binding site on the γ′ chain. 
 In the course of generating the γ/γ′ heterodimer variant, we produced a set of clones 
that expressed differing ratios of γ′ to γ chains.  Using these clones, we determined the 
correlation between the ratio of γ/γ′ mRNA produced and the ratio of γ/γ′ protein secreted by 
the cells.  Using immunoprecipitation, we also compared the ratio of γ/γ′ heterodimers 
formed compared to γ/γ and γ′/γ′ homodimers. 
 In vivo, the γ′ chain contains two sulfated tyrosine residues, Tyr 418 and 422 [3].  We 
used mass spectrometry to demonstrate that the γ′ chains expressed in CHO cells have this 
posttranslational modification. 
 
Introduction 
γ/γ′ Fibrinogen in Plasma 
 In a study of normal human blood samples, the concentration of γ/γ′ fibrinogen in 
plasma was found to be independent of age, gender, or total fibrinogen level [4].  The authors 
extended their study to individuals undergoing cardiac catheterizations, and found higher 
levels of γ/γ′ fibrinogen among patients diagnosed with coronary artery disease compared to 
their healthy cohorts.  Little is known, however, about the factors that influence an 
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individual’s level of γ/γ′ fibrinogen compared to γ/γ fibrinogen and whether elevated γ/γ′ 
fibrinogen is a cause, result, or epiphenomenon of coronary artery disease [4].  It is also 
unknown whether γ/γ′ heterodimers are assembled with much greater frequency than the rare 
γ′/γ′ homodimer simply due to probability or whether there is some mechanism that favors 
γ/γ′ production. 
Expression of Recombinant Fibrinogen 
 The process of recombinant fibrinogen production in CHO cells was developed in the 
Lord lab in 1993, and is shown in Figure 2.1.  The first step in this procedure is to transfect 
plasmids for two normal chains of fibrinogen (Aα and Bβ in this case) into Chinese hamster 
ovary cells, along with pRSVneo, a selection plasmid for neomycin resistance.  In the second 
step, we transfect cDNA encoding the mutated third chain (γ′ in this case) and a second 
resistance plasmid, pMSVhis, for histidinol resistance.  Neomycin and histidinol resistance 
are then used to select for CHO cell lines that carry the three chains of fibrinogen.  
Assembled fibrinogen is secreted into the culture medium, and collected once that medium 
has been changed to serum-free [5], [6].  Normal recombinant fibrinogen appears nearly 
identical to plasma fibrinogen by SDS-PAGE and electron microscopy and exhibits similar 
behavior during polymerization and FXIIIa-catalyzed cross-linking [5], [7]. 
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Figure 2.1: Recombinant fibrinogen is expressed in CHO cells by a two-step transfection 
procedure.  This protocol was developed by Binne et al. [5]. 
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Tyrosine Sulfation of Fibrinogen γ′ Chains 
 Unlike the human Aα and Bβ chains, the human fibrinogen γ′ chain contains sulfated 
tyrosines.  This sulfation was demonstrated by 35SO4 incorporation into fibrinogen expressed 
from primary cultures of rat and human hepatocytes.  Radioactivity corresponded to the γ′ 
chain only, as shown by electrophoresis, and was released as tyrosine sulfate by 
carboxypeptidase Y digestion or base hydrolysis [8], [9].  Sulfation of the γ′ chain was also 
demonstrated in recombinant fibrinogen expressed in BHK cells by 35SO4 incorporation [10].  
The sulfation sites on human fibrinogen were localized to tyrosines 418 and 422 by 35SO4 
labeling of recombinant fibrinogen mutants [3]. 
 Sulfation of tyrosine occurs in the Golgi apparatus [8].  Transfer of a sulfate from the 
donor PAPS (3′-phospho-adenosine 5′-phosphosulfate) to tyrosine is catalyzed by the 
enzyme TPST (tyrosylprotein sulfotransferase).  There are three characteristics that are 
considered consensus features for tyrosine sulfation sites: 
1) Acidic amino acids are prevalent; typically one is found at position -1 and several are 
found between -5 and +5 while few basic amino acids are located in this region. 
2) A turn-inducing amino acid must be present at the site, typically a proline or glycine. 
3) Steric hindrance is minimized due to a lack of disulfide bonds and glycosylations in 
the region [11]. 
Until now, the γ′ chain has never been expressed in CHO cells, although other tyrosine-
sulfated coagulation proteins have been.  Recombinant factor VIII expressed in CHO cells 
was found with two of three putative tyrosine-sulfation sites completely sulfated; the third 
was partially sulfated.  This diminished sulfation was attributed to limited accessibility of the 
sulfation site [12].  Recombinant factor V expressed in CHO cells displayed complete 
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sulfation of the two predicted sites [13].  These results suggest that CHO cells are capable of 
tyrosine sulfation in general; in particular, sulfation of the γ′ chain of fibrinogen has been 
confirmed by our mass spectrometry studies. 
 
Materials and Methods 
Materials 
 All chemicals and supplies were obtained from Fisher (Hampton, NH) or Sigma-
Aldrich (St. Louis, MO) unless otherwise described.  Human adult female liver first strand 
cDNA was purchased from Stratagene (La Jolla, CA).  Restriction enzymes and buffers were 
purchased from New England Biolabs (Ipswich, MA).  Taq polymerase, T4 DNA ligase, 
Superscript II RNaseH - reverse transcriptase, and penicillin/streptomycin were purchased 
from Invitrogen (Carlsbad, CA).  Expression vectors, DMEM-F12, Nu serum, bovine calf 
serum, and aprotinin have been previously described [5]. Antibodies were obtained from the 
following sources:  rabbit polyclonal anti-human fibrinogen and HRP-conjugated goat anti-
rabbit IgG from DAKO (Carpinteria, CA); rabbit polyclonal anti-fibrinogen γ chain (NC-15) 
custom antisera from Hazleton Research Products (Princeton, NJ); monoclonal anti-human 
fibrinogen Aα-chain N-terminus (Y-18) from Dr. W. Nieuwenhiuzen (Foundation of Liver 
Cell and Endothelial Cell Technology, Netherlands); polyclonal goat anti-human fibrinogen 
and HRP-conjugated goat anti-human fibrinogen from Cappel (Cochraville, PA); IF-1 
monoclonal calcium-dependent anti-fibrinogen antibody from Kamiya Biomedical (Seattle, 
WA); 4A5 monoclonal mouse anti-human fibrinogen γ chain a kind gift from from Dr. Gary 
Matsueda at Bristol Myers Squibb (Princeton, NJ); and 2G2H9 mouse monoclonal anti-
human fibrinogen γ′ chain a kind gift from Dr. David Farrell (Oregon Health and Sciences 
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University) and also purchased from Upstate (Charlottesville, VA).  Powdered insulin-
transferrin-sodium selenite was obtained from Roche (Indianapolis, IN) or Sigma-Aldrich. 
Sepharose Q Fast Flow Columns and CNBr-activated sepharose were purchased from 
Amersham Biosciences (Piscataway, NJ).  Absolute QPCR Reaction Mix, RT-PCR Tube 
Strips and UltraClear Cap Strips were purchased from ABGene (Rochester, NY).  RNase-
free water was obtained from Promega (Fitchburg, WI).   
Cloning the γ′ Chain from Human Liver cDNA 
 Unmodified pMLP-γ expression vector carrying normal γ chain (p674) was 
transformed into competent DH5α cells and the plasmid DNA isolated by mini-prep.  We 
confirmed the identity of the plasmid by digestion with AflIII.  The plasmid was then 
digested with BstXI and NotI, run on an agarose gel to separate the digested product, and 
purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) according to 
manufacturer’s protocol. 
 We used PCR to amplify sequence corresponding to the γ′ chain from human liver 
first strand cDNA using the following primers, prepared by the UNC Pathology Department 
Oligonucleotide Synthesis Facility: 
 Forward: CAC GCT GGC CAT CTC AAT GGA GTT TA 
  underlined bases are BstXI recognition site 
 Reverse: AGC ATT TGC GGC CGC CTA CAA ATC ATC CTC A 
  underlined bases are NotI recognition site 
This PCR product was digested using BstXI and NotI and purified as described above. 
 Digested, purified PCR product (0.05 µg) and digested, purified vector (0.05 µg) 
were incubated with 1 unit of T4 DNA ligase for 1 hour at room temperature, and the ligated 
DNA was transformed into competent DH5α cells.  We identified the presence of the γ′ 
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insert by digestion with AflIII alone and AflIII + Bsu36I, and confirmed the resulting γ′ 
plasmid sequence by Taq Dye Terminator Sequencing at the UNC Genome Analysis Facility.  
No inadvertent mutations arose during DNA manipulation.  Both the γ′ plasmid DNA and the 
p674 γ chain vector DNA were prepared in large quantities for transfection using the Qiagen 
Plasmid Maxi-prep kit (Qiagen, Valencia, CA) according to manufacturer’s protocol. 
Expression of γ′/γ′ and γ/γ′ Fibrinogen in CHO Cells 
 Transfection of γ′ plasmid into CHO cells carrying plasmids for the Aα and Bβ 
chains of fibrinogen was performed essentially as described [5].  Briefly, γ′ plasmid and 2 µg 
of histidinol resistance plasmid were incubated in the presence of calcium and then added to 
CHO cells that contained the Aα and Bβ chains of fibrinogen as well as a neo resistance gene 
for the antibiotic G418.  After four hours, we shocked the cells with 10% glycerol in DMEM-
F12 media for three minutes and then washed with G418 media (0.25 mM L-histidinol 
dihydrochloride, 40 mg/mL Geneticin (G418), in DMEM/F12 media with 5% Nu serum, 5% 
Calf Serum, and 0.01% Pen/Strep) and allowed them to recover.  For the γ′/γ′ clone, we 
transfected 18 µg of γ′ plasmid; for the γ/γ′ clone 18 µg of γ′ plasmid and 36 µg of p674 γ 
chain plasmid were mixed before transfection.  Appropriate clones for both γ′/γ′ and γ/γ′ were 
subcloned by infinite dilution. 
 The best clones for expression in roller bottles were selected based on fibrinogen 
production.  ELISA was used to measure the amount of fibrinogen secreted into serum-free 
media (0.01% Pen/Strep, 10 µg/mL insulin-transferrin-sodium selenite, 10 U/mL aprotinin in 
DMEM/F12) by each new γ′ clone.  In addition to the amount of fibrinogen expressed, 
selecting the best clone for γ/γ′ heterodimer roller bottles was done by measuring of the ratio 
of γ to γ′ chains produced.  This ratio was determined by Western blot.  Media samples for 
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Western blot were concentrated with a 100 kDa MWCO Centricon Eppendorf concentrator 
so that 0.25 µg of fibrinogen could be loaded onto the gel in 20 µL or less.  Samples were 
reduced by the method of Laemmli [14], and run at 60-80V on an 11% gel with a tall 
stacking gel.  This method of running the gel provided optimal separation between the γ and 
γ′ chains.  Western blots were developed using a polyclonal anti-fibrinogen antibody.  I used 
Scion Image (SCIONCorp, Frederick, MD) to quantify the ratio of γ : γ′ chains by 
densitometry. 
 Recombinant fibrinogen was expressed by growing cells to confluence in roller 
bottles, essentially as described [6], with the following modifications:  Microcarrier beads 
were omitted in later expressions once it was determined that they did not significantly 
improve yield.  After cells grew for six days in serum-free media, I collected media every 
day until the cells died, about 3 weeks later.  50 mL of fibrinogen-containing media was 
removed from the total 200 mL each day and proteases were inhibited by addition of 30 µM 
benzamidine, 6µM EDTA, 0.15% PMSF, and 0.01% NaN3 to collected media before 
freezing. 
Purification of Recombinant γ′/γ′ and γ/γ′ Fibrinogen 
 Recombinant fibrinogen was purified as described by Gorkun et al [7].  Briefly, an 
inhibitor cocktail was added to thawed media containing ~10 mg of fibrinogen.  Ammonium 
sulfate (either in saturated solution or granular form) was added gradually to precipitate the 
protein, the sample centrifuged, and precipitate was redissolved in pellet buffer.  The 
fibrinogen sample was purified on an IF-1 immunoaffinity column, a calcium-dependent 
monoclonal anti-fibrinogen antibody.  The resulting fibrinogen was dialyzed against one 
change of calcium-containing loading buffer, followed by extensive changes of HBS (20 mM 
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HEPES pH 7.4, 150 mM NaCl).  Concentration was measured spectrophotometrically using 
an ε280 of 1.51 for a 1 mg/mL solution, and the sample was analyzed by SDS-PAGE. 
 IF-1 purification was sufficient for γ′/γ′ fibrinogen, but γ/γ′ fibrinogen required further 
purification to isolate heterodimers.  I prepared a 4A5 anti-γ chain immunoaffinity column 
from CNBr-activated sepharose according to the manufacturer’s coupling protocol.  The 
column was equilibrated in 4A5 loading buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1mM 
CaCl2).  A sample of approximately 2.5 mg of IF-1 purified γ/γ′ fibrinogen was diluted to 
around 1 mg/mL in 4A5 loading buffer and applied to the column at 10 mL/hour.  During 
loading, absorbance increased as γ′/γ′ fibrinogen flowed through the column.  After loading, I 
continued the flow of 4A5 loading buffer until column effluent absorbance returned to zero.  
I increased flow rate to 50 mL/hour for 10 minutes to wash the column.  Fibrinogen 
containing γ chains was eluted with 1M guanidinium-HCl in TBS at 20 mL/hour, and 
fractions were immediately dialyzed against one change of 4A5 loading buffer to remove 
guanidinium and three changes of TBS (50 mM Tris pH 7.4, 150 mM NaCl), the last 
overnight. 
 Samples were removed from dialysis and concentrated to between 1 and 4 mg/mL in 
Amicon Ultra 100,000 MWCO Centrifugal Filter Devices.  Aliquots of 0.2 – 0.5 mg were 
loaded onto a Sepharose Q Fast Flow ion-exchange column equilibrated in IEX buffer A (39 
mM Tris pH 8.5 with H3PO4).  Proteins were eluted in increasing concentrations of IEX 
buffer B (190 mM Tris pH 2.43 with H3PO4) using the following program: 
0-15 minutes: 0% B (equilibrate) 
15-55 minutes: 0 – 100% B (gradient) 
55-65 minutes: 100% B (wash) 
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65-66 minutes: 100 – 0% B (regenerate) 
66-76 minutes: 0% B 
γ/γ′ Heterodimers eluted at 55% buffer B; fractions were collected, dialyzed into HBS, 
concentrated as described above, and analyzed by SDS-PAGE. 
Mass Spectrometry 
 Pure recombinant γ′/γ′ fibrinogen was dialyzed into 50 mM ammonium bicarbonate, 
pH 7.4 at a concentration of 0.68 mg/mL.  Protein digestion and mass spectrometry were 
performed by the UNC Proteomics Core Facility, essentially as described [15].  In brief, each 
sample was digested with trypsin in solution and analyzed by QTOF, followed by MS/MS 
fragmentation analysis.  A UNC Proteomics in-house version of the MASCOT search engine 
was used to search for matching fragments, with tyrosine sulfation selected as a possible 
post-translational modification. 
Quantitation of γ and γ′ mRNA 
 Quantitative RT-PCR was used to determine the relative levels of γ and γ′ message in 
each of seven CHO cell lines.  Cell line A is the normal recombinant fibrinogen cell line that 
expresses only γ chains, while cell line B is the γ′/γ′ clone that expresses only γ′ chains.  The 
remaining cell lines all express both γ and γ′ chains in different ratios.  Cells from each line 
expressed fibrinogen into serum-free media in a 10 cm cell culture dish for one week.  Media 
was collected and saved for analysis while RNA was harvested from the cells by the UNC 
Gene Expression facility according to the protocol of Kim et al. [16]. 
 Primers and probes are described in the text and were prepared by the UNC 
Pathology Department Oligonucleotide Sequencing Facility.  RT-PCR reactions were set up 
in 30 µL in 1 mM EDTA prepared in RNase-free water as follows: 
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10 µL of RNA diluted between 1:5 and 1:25 
15 µL QPCR mix containing 5 U reverse transcriptase 
0.5 µL of 0.1 µg/µL forward primer 
0.5 µL of 0.1 µg/µL reverse primer 
1 µL of 20 µM probe 
The ABI Prism 7700 program ran as follows: 
1) 48°C for 30 minutes – reverse transcription 
2) 95°C for 10 minutes – polymerase activation 
3) 95°C for 15 seconds – double-stranded DNA denaturation 
4) 60°C for 1 minute – annealing and extension 
Steps 3 and 4 are repeated 40 times.  Fluorescence of the reporter FAM is monitored. 
 A threshold above which the fluorescence exceeds background noise was determined 
for each experiment, and the number of cycles required for each sample’s fluorescence to 
reach this threshold (Ct) was recorded.  Ct is inversely proportional to the amount of message 
originally present in the sample.  Ct values for γ and γ′ message within each cell line were 
compared using the equation: 2^(γCt - γ′Ct). 
 Although it is common to run a control RT-PCR reaction with GAPDH, β-actin, or 
another housekeeping gene, that was deemed unnecessary in these experiments since the 
ratio of γ′ to γ chains for each clone is being compared, not their actual amounts.   Several 
preliminary experiments were performed to determine the optimal amount of mRNA 
template to use for each individual set of primers. 
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Quantitation of γ and γ′ Protein 
 ELISA assays were used to determine the ratio of γ′ to γ chains expressed in each 
clone essentially as described above, but using chain-specific capture antibodies.  Microtiter 
plate wells were coated with either 120 µL of 1:1000 4A5 to determine γ chain concentration 
or 120 µL of 1:333 2G2H9 to determine γ′ chain concentration.  Standard curves were 
prepared with serial dilutions of either γ/γ clone A media (4A5 plates) or γ′/γ′ clone B media 
(2G2H9 plates).  Samples were prepared from the serum-free media collected from the cells 
whose RNA was harvested for RT-PCR; media was diluted between 1:4 and 1:20 to yield 
optimal signal. 
Immunoprecipitation 
 4A5-sepharose beads were prepared in Eppendorf tubes from 0.03 g CNBr-activated 
sepharose.  Beads were incubated for 10 minutes in 1 mL washing solution (1 mM HCl) to 
swell.  They were washed with 6 mL of coupling buffer (0.1 M NaHCO3/Na2CO3 pH 8.3, 0.5 
M NaCl) and allowed to rotate for 1 hour at room temperature with 4A5 ascites fluid diluted 
1:500 in 0.5 mL coupling buffer.  The beads were again washed with coupling buffer (7.5 
mL) and then allowed to sit for 2 hours in 1 mL blocking buffer (1 M ethanolamine in H2O, 
pH 8.0) to quench reactive sites.  Finally, the beads were washed alternatively three times 
each with 1.5 mL washing buffer (0.1 M NaCH3CO2 pH 4.0, 0.5 M NaCl) and Tris buffer 
(0.1 M Tris-HCl pH 8.0, 0.5 M NaCl). 
 For immunoprecipitation, each batch of beads was split into five tubes.  Each tube 
was blocked with 100 µL of 10% BSA for 30 minutes, and then 1 mL of 1 µg/mL protein 
was added.  The beads were incubated at 4°C for 1 – 2 hours while rotating, the supernatant 
was removed, and beads were washed four times with 1 mL ice-cold wash buffer (50 mM 
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Tris pH 7.4, 300 mM NaCl, 5 mM EDTA, 0.1% Triton-X) and once with HBS.  Supernatant 
was removed and replaced with 3 µL HBS, 8 µL 6X Laemmli buffer, and 2 µL BME.  
Samples were loaded onto an 11% gel and run as described above for optimal γ/γ′ chain 
separation.  Bands were transferred to nitrocellulose, the Western blot developed with 
polyclonal anti-fibrinogen antibody, and the intensity of bands was quantified by 
densitometry using SCION Image. 
 
Results 
Construction of the γ′ Chain Plasmid 
 I constructed an expression vector for the γ′ chain of fibrinogen from the pMLP-γ 
expression vector, p674.  This vector was digested with BstXI and NotI.  The γ′ insert was 
amplified from human liver first strand cDNA using primers that incorporated the BstXI and 
NotI restriction sites.  The insert was digested with these enzymes and ligated into the γ chain 
vector.  Initially, I identified samples with the correct construction of the γ′ chain plasmid by 
restriction digestion with the enzymes AflIII and Bsu36I.  As shown in Figure 2.2, digestion 
of a correctly constructed p674 vector + γ′ insert plasmid will yield a characteristic banding 
pattern absent if the γ′ insert is not incorporated.  These bands will be 3004 bp, 1279 bp, 721 
bp, and 658 bp.  An incorrectly ligated vector will lack the Bsu36I site and thus only be 
digested into fragments of 4283 bp, 721 bp, and 658 bp.  Figure 2.3 shows the difference 
between positive and negative clones in the initial ligation transformation.  Colony 1 did not 
contain the γ′ insert because its digestion pattern did not change when Bsu36I was added to 
AflIII.  Colony 2 likely did contain this sequence because two smaller bands were produced 
upon addition of Bsu36I. 
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p674 gammaprime
5662 bp
BstXI (2567)
NotI (2820)
Bsu36I (2802)
AflIII (144)
AflIII (865)
AflIII (1523)
 
Figure 2.2.  Sequence coding for the γ′ extension to the γ chain was inserted into vector p674 
using BstXI and NotI.  Addition of the γ′ sequence introduces a unique Bsu36I site that 
allows for identification of positive clones when the plasmid is digested with a combination 
of Bsu36I and AflIII. 
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Figure 2.3.  1% agarose gel showing different digestion patterns for positive and negative 
clones.  The band on the left for each clone is digestion with AflIII only; the band on the 
right is digestion by AflIII + Bsu36I.  Colony 1 shows no difference between AflIII and 
AflIII + Bsu36I digestion patterns.  Colony 2 shows that the largest band (~4000 bp) is split 
in two with the addition of Bsu36I. 
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A positive clone was selected and sequenced in both the forward and reverse directions 
through the length of the coding region.  The results confirmed insertion of the γ′ sequence 
with no change in the remaining cDNA. 
Expression of γ′ Variants by CHO Cells 
 After sequencing, I transfected the γ′ plasmid into CHO cells that already carried 
plasmids for the Aα and Bβ chains of fibrinogen.  This transfection produces γ′/γ′ 
homodimer protein.  I grew 24 clones of this transfected cell line and selected the clone with 
the highest level of fibrinogen secretion to be grown in roller bottles.  This clone is also clone 
B, used for the γ/γ′ ratio quantitation experiments.  To prepare my heterodimer protein, I 
transfected both γ and γ′ plasmids into the CHO cell line with Aα and Bβ chains.  Five of the 
clones from this transfection became cell lines C-G, used in the γ/γ′ ratio quantitation 
experiments (cell line A comes from normal, recombinant γ/γ fibrinogen).  I chose the clone 
with the highest level of fibrinogen production that also expressed a relatively equal ratio of γ 
and γ′ chains to be used in roller bottle expression. 
Because fibrinogen expression levels were low, I subcloned the two CHO cell lines 
used for γ′ variant expression.  Subcloning led to a distinct improvement in the expression of 
the γ′/γ′ fibrinogen clone.  Prior to subcloning, media was expressed with fibrinogen at a 
level of around 1.4 µg/mL and after subcloning it was expressed at 2.6 µg/mL.  Subcloning 
did not change the expression level of the γ/γ′ clone as drastically (2.3 µg/mL to 2.8 µg/mL); 
however, it did allow for selection of a clone with a γ/γ′ ratio closer to 50%.  As determined 
by Western blot, in the new γ/γ′ clone, 63% of the total γ and γ′ chains were γ′, while 85% 
were γ′ in the old clone.  This change translates to a significant difference in the possible 
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percentage of heterodimers; 47% of molecules could form heterodimers with the new clone 
versus only 26% for the old. 
 In early attempts at expressing the γ′ variants, a significant percentage of the Aα 
chain was proteolytically degraded.  To minimize this degradation, I made several 
adjustments to the usual expression protocol [6].  Instead of collecting 100 mL of media 
every 2-3 days, I collected 50 mL every day to keep fibrinogen levels low.  A cocktail of 
protease inhibitors (30 µM benzamidine, 6µM EDTA, 0.15% PMSF, and 0.01% NaN3) was 
also added to the media right after collection, rather than 0.15% PMSF alone.  Figure 2.4 
shows a Western blot performed with an antibody specific to the Aα chain (Y-18) that 
demonstrates an early collection of fibrinogen with significant Aα chain degradation, while 
fractions collected with the modifications described above have barely detectable degradation 
bands. 
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Figure 2.4: Western blot using anti-Aα chain N-terminus antibody (Y-18).  The degraded Aα 
sample (from a degraded preparation of γ/γ fibrinogen) shows the full-length Aα band as well 
as two degradation products below it.  The bands to the right of this standard are every third 
collection from two clones (B and D) expressed with adjustments to decrease proteolytic 
degradation.  Media samples were concentrated in 100kDa MWCO Eppendorf concentrators 
and concentrated samples were prepared to load 0.25 µg of fibrinogen. 
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Purification of Recombinant γ′/γ′ and γ/γ′ Fibrinogen 
 Recombinant fibrinogens were purified from culture media by immunoaffinity 
chromatography as described [7].  While this method was sufficient for γ′/γ′ fibrinogen, it did 
not separate γ/γ′ heterodimers from the γ/γ and γ′/γ′ homodimers that were all produced by 
the heterodimer cell line.  The IF-1 antibody bound to all three of these fibrinogens.  Others 
[17] have developed a DE-52 ion-exchange column to separate γ/γ′ heterodimers from γ/γ 
homodimers in plasma fibrinogen based on their charge difference.  However, this method 
did not work for our mixture of heterodimers and homodimers because it was unable to 
separate γ/γ′ heterodimers from γ′/γ′ homodimers.  Therefore, I developed a purification 
protocol that pairs ion-exchange chromatography with immunoaffinity chromatography 
(Figure 2.5).  Unfractionated IF-1 purified γ/γ′ fibrinogen (with γ/γ homodimers, γ′/γ′ 
homodimers, and γ/γ′ heterodimers) was subjected to a 4A5 immunoaffinity column.  As 
shown in Figure 2.6, γ′/γ′ homodimer fibrinogen did not bind to this column.  It eluted in the 
flow-through (2.6B), while a mixture of γ/γ and γ/γ′ fibrinogen specifically eluted in 1 M 
guanidine-HCl in TBS. 
The product of the 4A5 column was applied to an ion-exchange column to separate 
the γ/γ homodimers from the γ/γ′ heterodimers.  The heterodimers were collected from the 
column, dialyzed, and concentrated.  Figure 2.7 shows a characteristic chromatogram from 
the ion-exchange column and pure γ/γ′ heterodimers as demonstrated on SDS-PAGE.  
Densitometry showed the presence of approximately 50% each of γ and γ′ chains in the 
purified γ/γ′ heterodimer sample. 
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Figure 2.5: Purification of γ/γ′ heterodimers is a two-step process. 
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Figure 2.6: A) Elution profile for 4A5 immunoaffinity column.  IF-1 purified γ/γ′ fibrinogen 
is loaded in 50 mM Tris pH 8.0, 150 mM NaCl, 1mM CaCl2.  Bound fibrinogen is eluted with 
1 M guanidine-HCl in TBS and immediately dialyzed.  B) 11% reducing gel of 4A5 column 
fractions.  Molecular weight markers are noted on the left of the gel and band identifications 
are on the right.  Elution peak and shoulder are in the first three wells, followed by flow-
through from column loading.  The last three wells are standards: pure γ/γ fibrinogen, pure 
γ′/γ′ fibrinogen, and an equimolar mix of γ/γ and γ′/γ′ fibrinogen. 
 45 
 
 
Figure 2.7: A)  Samples eluted from the 4A5 column were run on the ion-exchange column 
to separate γ/γ′ heterodimers from γ/γ homodimers.  The diagonal line reflects the gradient of 
0-100% buffer B used to elute fibrinogen from the column (see Methods).  B)  11% reducing 
gel with molecular weight indicated on the left and bands identified on the right.  γ/γ′ 
fractions from ion-exchange were pooled, dialyzed, concentrated, reduced, and run on the 
gel.  Standards are recombinant γ/γ, γ′/γ′, and a 50% mixture of γ/γ and γ′/γ′. 
B 
 
A 
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Determination of Tyrosine Sulfation 
 Recombinant γ′/γ′ fibrinogen was digested with trypsin and the fragments analyzed 
by QTOF and MS/MS fragmentation to determine whether the γ′ chain of CHO-expressed 
recombinant fibrinogen was sulfated.  Analysis of the QTOF results by MASCOT search 
identified fibrinogen Aα, Bβ, and γ′ chains as significant hits, confirming that this protein 
sample is indeed γ′/γ′ fibrinogen.  Of the γ′ chain hits, four peptides corresponded to the 
relative molecular mass of the unsulfated γ′ fragment (2502 Da), while nine matched the 
singly sulfated γ′ relative molecular mass (2582 Da).  These results indicate that sulfation did 
take place during fibrinogen production in CHO cells and that at least one of the tyrosines in 
the γ′ peptide was sulfated. 
 MS/MS fragmentation (see Figure 2.8) analysis of the sulfated γ′ peptide peaks 
showed that tyrosine 422 was sulfated; there is no evidence that 418 was sulfated also.  
However, because sulfation is a labile post-translational modification, it is possible that this 
sulfate may have been lost during mass spec manipulations. 
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Figure 2.8.  MS/MS fragmentation of γ′ peptide.  The peptide sequence is shown above the 
mass spec plot.  Fragment y(7) is split between the two tyrosines in the peptide.  It is found at 
m/z 944, indicating that tyrosine 422 is sulfated. 
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Quantitation of γ/γ′ mRNA 
 Expression of the γ′ chain in the CHO system was studied by comparing the ratio of γ 
to γ′ chain RNA inside the cells with the ratio of γ to γ′ chain protein expressed and secreted 
from the cells.  RT-PCR was used to compare the amount of mRNA for γ chains to the 
amount of mRNA for γ′ chains.  As illustrated in Figure 2.9, we designed a common forward 
primer, a common probe, and two reverse primers, one that would amplify mRNA coding for 
the γ chain and another that would amplify γ′ mRNA.  Sequences, characteristics, and 
location of the primers and probe are shown in Table 2.1. 
 For each clone, A-G, RT-PCR experiments were performed in triplicate for each 
primer set: common forward with γ reverse and common forward with γ′ reverse.  Data from 
the experiment was reported as a Ct, the number of cycles required to reach a threshold 
fluorescence level above background.  This threshold is the same for all samples in a given 
experiment.  The ratio of γ′ to γ mRNA was calculated as follows: 
 γ′ mRNA / γ mRNA = 2^(γCt - γ′Ct) 
The percentage of γ′ mRNA out of total γ + γ′ message in each sample was determined: 
 % γ′ mRNA = 100 – (100 / (1 + γ′ : γ ratio))1 
Table 2.2 shows the results of the RT-PCR experiments. 
                                                
1 For example, if we determine that the two Ct values are equal at 60 cycles, then γ′ / γ = 
2^(60 – 60) = 2^(0) = 1.  Then % γ′ mRNA = 100 – (100 / (1 + 1)) = 50% γ′ mRNA and 50% 
γ mRNA, just as we would predict from equal Ct values. 
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γ mRNA Sequence 
 
 
5´                   3´ 
 
γ´ mRNA Sequence 
 
 
5´            
 
 Common Forward Primer    Common Sequence 
 Common Probe     Unique γ Sequence 
 Unique γ Reverse Primer    Unique γ′ Sequence 
 Unique γ′ Reverse Primer 
Figure 2.9: Design of primers and probes for RT-PCR. 
3´ 
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Primer and Probe Sequences for RT-PCR 
Primer 
or Probe 
Sequence Tm 
(°C) 
%GC  Recognizes 
Common 
Forward  
CCACTATGAAGATAATCCCATTC 52 39 γ and γ′  
1223 - 1245 
γ Reverse CGGTCTTTTAAACGTCTCCAGC 55 50 γ 1300 – 1314 
and 9 bases of 
adjacent 
plasmid 
γ′ 
Reverse 
TCATCCTCAGGGTAAAGTGAGTC 55 48 γ′ 1333 – 1355 
Common 
Probe 
CCCAGGTGGTGTTGCTGTCCTTCTC 63 60 Reverse 
complement of 
γ and γ′ 1262 - 
1286 
Table 2.1.  Sequences, melting temperature (°C), % GC content, and mRNA sequence 
recognized by each primer or probe.  The common probe contains the 5′ reporter dye FAM 
and the 3′ quencher TAMRA.  mRNA of interest is transcribed into a DNA template by Taq 
DNA polymerase using the forward and reverse primers.  The DNA template is then 
amplified through 40 PCR cycles, during which the probe anneals.  Each time the 
complementary sequence is extended, however, the probe will be hydrolyzed, separating the 
TAMRA quencher from the FAM reporter.  This process releases fluorescence that can be 
quantified by the ABI Prism 7700 Sequence Detector and is proportional to the number of 
copies of the mRNA template present. 
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Clone % γ′ mRNA 
A (all γ) 0.000 +/- 0.001 
B (all γ′) 99. 9 +/- 0.1 
C 67.5 +/- 9.1 
D 65.8 +/- 17.8 
E 29.3 +/- 11.8 
F 98.3 +/- 2.0 
G 98.2 +/- 1.7 
Table 2.2. % γ′ mRNA for seven clones determined from RT-PCR experiments as described 
above. 
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Quantitation of γ/γ′ Protein 
 I used ELISA to determine the concentrations of γ and γ′ chain protein produced by 
each cell line with the γ-specific monoclonal antibody 4A5 to determine the concentration of 
γ chains and the γ′-specific antibody 2G2H9 to measure the concentration of γ′ chains.  To 
determine the ratio of γ′ to γ chains in the expressed protein, I needed a way to relate the 
concentrations determined by each antibody to one another.  I measured the total 
concentration of γ chains (2 x [fibrinogen]) for clone A (γ chains only) and the total 
concentration of γ′chains for clone B (γ′ chains only) media using a Cappell polyclonal anti-
fibrinogen plate and pure plasma fibrinogen as a standard.  The clone A media ([γ] = 5.97 
µg/mL) was then used to create a standard curve of γ chains on the 4A5 plate while the clone 
B media ([γ′] = 1.42 µg/mL) was used to prepare a standard curve of γ′ chains on the 2G2H9 
plate.  Each of six media samples for each clone was then measured in triplicate on each 
plate.  Results of these experiments are shown in Table 2.3. 
By comparing the RT-PCR data with the ELISA data for these six γ′-chain producing 
clones, we investigated the level of expression for the γ′ chain compared to the γ chain in 
CHO cells.  As shown in Figure 2.10, the percentage of γ′ message RNA in each cell line 
(red) approximated the percentage of γ′ protein in total fibrinogen (blue). Clones that showed 
significant differences in mRNA and protein level, as indicated by a Student’s T-test are 
marked with an asterisk.  Although there is a slightly greater percentage of γ′ protein than 
γ′mRNA in clones C and D, this trend does not hold for all five γ/γ′ clones.  Thus, in CHO 
cells, both the γ and γ′ chains appear to be produced at the same level.
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Clone [γ  Chain] (µg/mL) [γ′ Chain] (µg/mL) % γ′ Protein 
A (all γ) 11.0 +/- 3.3 0.0089 +/- 0.0126 0.076 +/- 0.106 
B (all γ′) 0.00 +/- 0 3.42 +/- 1.36 100 +/- 0 
C 0.349 +/- 0.061 6.26 +/- 2.10 94.2 +/- 2.1 
D 0.834 +/- 0.122 5.06 +/- 1.72 84.7 +/- 4.5 
E 4.35 +/- 0.73 1.10 +/- 0.42 20.0 +/- 7.2 
F 0.116 +/- 0.027 2.22 +/- 0.66 94.6 +/- 2.5 
G 0.0486 +/- 0.0161 3.43 +/- 1.46 98.5 +/- 0.5 
Table 2.3. % γ′ Chain expressed in seven clones, as determined by ELISA.  [γ chain] and [γ′ 
chain] reported in µg/mL from the average of 7 experiments.  % γ′ protein was calculated 
from the % γ′ protein determined in each experiment and is reported +/- standard deviation. 
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Figure 2.10. Comparison of mRNA and protein levels for γ/γ′ containing CHO cell lines.  
Standard error is plotted as error bars and p values < 0.05 are shown with an asterisk. 
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Quantitation of Heterodimer Percentage 
 I used immunoprecipitation experiments to measure the percentage of heterodimers 
formed in a sample of fibrinogen expressed by CHO cells that contained a mixture of γ/γ 
homodimers, γ′/γ′ homodimers, and γ/γ′ heterodimers.  I covalently coupled anti-γ chain 
antibody 4A5 to CNBr-sepharose, and incubated it with a sample of purified, but 
unfractionated fibrinogen for two hours.  After washing, the only fibrinogen still bound to the 
beads should have been that fibrinogen that contained a γ chain.  Control experiments 
demonstrated that the addition of 10% BSA to the beads as a blocker and the appropriate 
design of wash buffer prevented nonspecific adsorption of fibrinogen to the beads; as shown 
in Figure 2.11A, immunoprecipitation of γ′/γ′ fibrinogen with 4A5-sepharase did not pull 
down any protein. 
 Assuming a 1:1 ratio of γ:γ′ chains in a particular clone, the ratio of expected products 
is: 
 1 (γ/γ) : 2 (γ/γ′) : 1 (γ′/γ′) 
In any clone, the expected % heterodimer formed is: 
 (2 * (%γ) * (%γ′))*100 
when (%γ) and (%γ′) are expressed as decimal percents of total γ(′) chains.   
Clone D fibrinogen was chosen for immunoprecipitation experiments because it was 
expected to produce the greatest proportion of heterodimers.  After subcloning the CHO cell 
line, Western blots of pure protein expressed by clone D in roller bottles indicated that the 
percentage of γ chain protein in this clone was 37 +/- 5% and the percentage of γ′ chain 
protein was 63 +/- 5%.  Therefore, the expected percentage of γ/γ′ heterodimers in the protein 
was 46 +/- 3%. 
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 Results of a representative immunoprecipitation experiment are shown in Figure 2.11.  
γ/γ and γ′/γ′ fibrinogen standards mark the locations of the γ and γ′ chains, respectively, while 
the clone D standard shows that the unfractionated sample has a greater percentage of γ′ 
chains than γ chains.  Immunoprecipitation of γ′/γ′ fibrinogen shows that no γ′ chains are 
recognized by 4A5, while immunoprecipitation of γ/γ homodimer has just γ chains.  
Immunopreciptiation of a 50% mixture of γ/γ and γ′/γ′ leads to just γ chains visible on the 
blot (data not shown).  Immunoprecipitation of clone D results in a mixture of γ and γ′ 
chains. 
Densitometry of the clone D immunoprecipitation is shown in Figure 2.11B.  From 
this calculation, approximately 45% of the total γ or γ′ chains pulled down in the IP were γ′ 
chains.  Since the only γ′ chains pulled down during the immunoprecipitation reaction were 
those that were part of heterodimers, this experiment showed that 60% of the fibrinogen 
molecules produced by this clone were heterodimers2.  The average from all 
immunoprecipitation experiments showed that the γ/γ′ fibrinogen sample contained 52 +/- 
12% heterodimers.  Within error, this result was the same as the expected 46 +/- 3% 
heterodimers, suggesting that no impediment existed to heterodimer formation.  
                                                
2 Assume intensity is proportional to the number of chains pulled down by the IP and that 
4A5 will bind to any γ chain with equal affinity.  37% of the γ and γ′ chains in clone D are γ 
chains, so if γ intensity = 525, then this is 37% of the total number of γ or γ′ chains, or 1419 
chains.  Because there are two γ or γ′ chains per molecule, there are 709 molecules in the 
sample.  The only γ′ chains pulled down in the IP are part of heterodimers, and every 
heterodimer has a γ′ chain that shows up on the blot.  Therefore, the % heterodimers is 426 / 
709 = 60%. 
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Chain Intensity 
γ′ 426 
γ 525 
Figure 2.11.  A) Fibrinogen samples immunoprecipitated with 4A5 (anti-γ chain)-conjugated 
sepharose beads and run on an 11% reducing gel, probed with polyclonal anti-fibrinogen 
antibody.  γ/γ, γ′/γ′, and clone D standards were run directly on the blot without 
immunoprecipitation.  Immunoprecipitated samples were washed with washing buffer and 
HBS, then boiled in 6X Laemmli with BME.  Samples were spun down and the supernatant 
was loaded.  B) Densitometric scan of IP-Western blot with peaks marked and calculated 
intensities listed in the table below. 
A 
B 
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Discussion 
 We have successfully produced milligram quantities of recombinant γ′/γ′ homodimer 
and γ/γ′ heterodimer fibrinogen.  With proper collection technique, Aα-chain degradation can 
be mostly avoided.   
Mass spec experiments show that the γ′ chains produced in CHO cells are, indeed, 
sulfated.  This analysis revealed a combination of unsulfated and singly sulfated γ′ chains.  
Because sulfation is an inherently unstable modification, especially under the conditions used 
for electrospray ionization [18], it is not appropriate to conclude that the amount of sulfation 
detected by mass spec analysis is an exact reflection of what exists in the protein sample.  
These results simply show that tyrosine sulfation does take place during γ′ chain production 
in CHO cells, particularly on tyrosine 422.  The presence of unsulfated peptides does not 
necessarily mean that a population of fibrinogen is unsulfated; nor does the absence of 
doubly sulfated peptides mean that tyrosine 418 cannot be sulfated.  The results of this 
experiment simply show that the tyrosine sulfation modification, which provides the extra 
negative charge carried by the fibrinogen γ′ chain, takes place in CHO cells during fibrinogen 
expression. 
Sabo et al. have recently shown that only one modified tyrosine is absolutely required 
for thrombin binding, and that tyrosine 422 is more important in this role than is tyrosine 
418.  They prepared synthetic γ′ peptides with one or both tyrosine residues phosphorylated 
and used them in NMR studies of the structure of the γ′ / thrombin complex.  
Phosphorylation is not acid-labile like sulfation, but still provides the same negative charge.  
They showed that when the doubly phosphorylated peptide was mixed with thrombin, lines 
in the 1D-NMR spectrum of the mixture broadened compared to the spectrum of the peptide 
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alone.  This broadening suggests that conformational changes have taken place in the peptide 
upon binding.  When the peptide phosphorylated only at tyrosine 422 is added to thrombin, 
significant line broadening takes place, but very little occurs for the peptide phosphorylated 
at tyrosine 418 [19].  These findings confirm that even if our γ′ chains are only sulfated at 
residue 422, they should function in a manner similar to the doubly sulfated γ′ chain. 
In 2002, Okumura and coworkers studied expression of truncated γ-chain mutant 
fibrinogens in CHO cells.  While they found equal message levels for fibrinogens that 
terminated between γ379 and the normal C-terminus γ411, they discovered varying amounts 
of these fibrinogens in cell lysates and culture medium.  Specifically, mutants with γ chains 
that ended at or before residue 386 were never secreted from the CHO cell, while those with 
longer chains were secreted, at levels that increased with increasing length of the γ chain.  
From these studies, they concluded that the C-terminus of the γ chain is essential for normal 
assembly of the fibrinogen molecule, and therefore its secretion from CHO cells [20]. 
 These results prompted us to consider whether changing the C-terminus of the γ chain 
by including the γ′ sequence would affect fibrinogen assembly and secretion.  We find no 
suppression in γ′ chain production, and perhaps even some preference for γ′ formation 
compared to γ, although this trend is only seen in two of the clones studied.  Therefore, there 
is nothing inherent in the γ′ sequence that would slow this chain from being assembled and 
secreted by CHO cells.  This finding suggests that it is only the relative amount of γ and γ′ 
plasmid present in each cell line that determines the ratio of γ to γ′ protein expressed in our 
CHO system.  
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 As shown in our immunoprecipitation experiments, fibrinogen γ/γ′ heterodimers form 
during expression in CHO cells at approximately the frequency expected for random 
association of chains.  There is no preference for either heterodimer or homodimer assembly. 
 Information about fibrinogen expression in CHO cells may or may not translate to 
humans; however, the experiments described in this chapter could be carried out in Hep-G2 
cells or systems that more closely mimic human fibrinogen production to learn about human 
γ′ fibrinogen expression. 
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CHAPTER THREE 
 
 
CHARACTERIZING THE POLYMERIZATION OF RECOMBINANT γ′/γ′ AND γ/γ′ 
FIBRINOGEN VARIANTS 
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Summary 
 We characterized the polymerization of recombinant γ′/γ′ and γ/γ′ fibrinogen and 
compared it to recombinant γ/γ fibrinogen with normally spliced γ chains.  Measurement of 
turbidity during the course of polymerization at three concentrations of calcium showed a 
diminished rate of polymerization and lower final absorbance for γ′/γ′ fibrinogen compared 
to γ/γ fibrinogen.  γ/γ′ Fibrinogen displayed intermediate Vmax and final absorbance values 
compared to γ′/γ′ and γ/γ. At 10 µM CaCl2, γ′/γ′ fibrinogen had a longer lag time than γ/γ 
fibrinogen, but when the calcium concentration was increased to 2 or 5 mM, the lag time for 
γ′/γ′ fibrinogen normalized to that of γ/γ fibrinogen.  Fibrinopeptide release assays monitored 
by HPLC indicated that FpA release from γ′/γ′ and γ/γ′ fibrinogen was normal while the rate 
constant for FpB release from γ′/γ′ fibrinogen was increased. 
 
Introduction 
Polymerization 
 Fibrin polymerization is typically observed by changes in turbidity, a technique first 
explored for fibrin in 1947 by Ferry and Morrison [1].  The order and rate of reactions that 
take place during fibrin polymerization were quantitated by use of stopped flow light 
scattering in 1979 by Hantgan and Hermans.  Measurements with rate-limiting 
concentrations of thrombin suggested that polymerization begins prior to FpB release, but 
experiments with reptilase-catalzyed polymerization showed that leaving FpB intact slows 
fiber formation.   Because light scattering measures the formation of small oligomers, 
Hantgan and Hermans demonstrated that the lag time observed in turbidity studies is due to 
the time required for protofibril formation prior to fiber formation.  This study espoused the 
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idea of a two-step mechanism for fiber formation; the polymerization of fibrin monomers 
into a protofibril followed by lateral aggregation of protofibrils into fibers [2].  
 The effects of particular variables on clot formation and final structure can be 
determined by monitoring polymerization by turbidity.  For example, Carr and coworkers 
used turbidity to show that at a given ionic strength, increasing calcium concentration to 5 
mM over the absence of added calcium increased both the rate of clot formation as well as its 
final turbidity or fiber thickness [3].  Turbidity measurements can also demonstrate 
differences in clot formation among variant fibrinogens.  Such analysis, for example, showed 
that clots formed from deglycosylated fibrinogen polymerized faster and with a higher final 
absorbance compared to normal fibrinogen, a difference that was not detected by clinical 
clotting assays [4]. 
 Weisel and Nagaswami developed a kinetic model to translate turbidity data into 
polymerization rate constants to describe fibrinopeptide A cleavage, fibrin monomer 
aggregation into protofibrils, and protofibril aggregation into fibers [5].  They used electron 
microscope images of fibrin(ogen) in various states of polymerization in combination with 
turbidity curves to demonstrate the validity this model.  Chemical reactions for each step of 
polymerization were described with appropriate kinetic equations and rate constants such that 
their combination would accurately generate the shape of a polymerization curve as 
measured by turbidity.  The lag time observed in typical polymerization curves was modeled 
by requiring oligomers to assemble up to a minimum length before aggregating into 
protofibrils.  A minimum length of around 10 – 20 monomers generates model 
polymerization curves that match well with experimental curves determined at physiological 
conditions.  The observation that turbidity levels off with time is modeled by using a rate 
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constant for protofibril growth that is larger than the rate constant for protofibril initiation, 
yielding fewer longer protofibrils rather than many short ones.  The power of this model lies 
in its ability to both predict the effect of changing conditions on clot formation, and to 
explain changes in experimentally-determined polymerization profiles on a mechanistic level 
[5]. 
Fibrinopeptide Release 
 While overall polymerization of a fibrinogen variant is often characterized by 
monitoring turbidity, the early steps of fibrinopeptide release may be analyzed by HPLC.  
The kinetic pathway for fibrinopeptide release and fibrin polymerization has been thoroughly 
characterized [6]; comparing rate constants for a mutant or variant fibrinogen polymerization 
compared to normal fibrinogen provides evidence of whether its change in structure 
influences polymerization. 
 The use of HPLC to quantify fibrinopeptide release was pioneered by Martinelli and 
Scheraga.  They first demonstrated the ability to separate bovine fibrinopeptides A and B by 
isocratic elution on HPLC [7], and then described an assay to measure kinetics of 
fibrinopeptide release from bovine fibrinogen using this detection method [8].  Higgins and 
Shafer refined the experiment to employ gradient elution for better separation of FpA and 
FpB.  They were then able to use this assay to characterize an inherited dysfibrinogenemia 
(Petoskey) that releases an abnormal FpA upon thrombin-cleavage [9].   
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Materials and Methods 
Materials 
 Recombinant γ′/γ′ and γ/γ′ fibrinogen were expressed and purified as described in 
Chapter Two.  Normal, recombinant γ/γ fibrinogen was prepared as described [10] and 
purified as described [11].  Human α-thrombin (lot 2690PR) was purchased from Enzyme 
Research Laboratories (South Bend, IN).  Synthetic fibrinopeptide standards were 
synthesized at the UNC Peptide Synthesis Facility (Chapel Hill, NC), according to the 
following sequences: 
FpA: ADSGEGDFLAEGGGVR 
FpB: QGVNDNEEGFFSAR 
All chemicals were purchased from Sigma or Fisher unless otherwise specified.  
Polymerization 
 I performed polymerization reactions in 100 µL in Corning half-area untreated 
polystyrene microtiter plates under the following conditions: 
 0.15 mg/mL fibrinogen (recombinant γ/γ, recombinant γ′/γ′, or recombinant γ/γ′) 
 20 mM HEPES pH 7.4 
 10 µM, 2.0 mM, or 5.0 mM CaCl2 
 NaCl to bring ionic strength to 0.15 
 1.0 nM (0.10 U/mL) α-thrombin 
10 µL of 10 nM α-thrombin in HBS was added to solutions of fibrinogen, HEPES, CaCl2, 
and NaCl prepared in 90 µL to initiate clot formation.  Turbidity was monitored on a 
SpectraMax 340PC microtiter plate reader from Molecular Devices at 350 nm every 10 
seconds for 90 minutes.  Data was recorded in SoftmaxPro version 4.3.1 (Molecular Devices, 
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Sunnyvale, CA).  Absorbance was plotted versus time for each polymerization curve.  Lag 
time was measured as the time when the change in OD first reached a non-zero slope.  Final 
absorbance of the clot was measured when the slope returned to zero.  Vmax (maximal rate of 
change) was determined from the five points on the curve with the highest slope as 
determined by Softmax. 
Fibrinopeptide Release 
 Recombinant fibrinogen (γ/γ, γ′/γ′, or γ/γ′) was diluted to 0.10 mg/mL in 20 mM 
HEPES pH 7.4, 150 mM NaCl, 1.0 mM CaCl2 (HBS+Ca).  I transferred aliquots (240 µL) of 
this solution to time = 0 and time = infinity Eppendorf tubes, and placed the remaining 2 mL 
in a 15-mL conical tube for reaction.  α-Thrombin (5000 U/mL) was diluted to 50 U/mL in 
HBS+Ca+0.1% polyethylene glycol.  A secondary dilution was prepared as 2 U/mL in 
HBS+Ca.  I initiated reaction by addition of 10 µL of 2 U/mL thrombin to the fibrinogen for 
0.010 U/mL thrombin (0.10 nM).  Aliquots (240 µL) were quickly transferred to Eppendorf 
tubes after mixing and were quenched at appropriate times (2, 5, 10, 20, 40, 80, 120 minutes) 
by boiling for 15 minutes.  All manipulations were completed within 90 seconds before the 
solution became viscous.  Thrombin (0.5 µL of 5000 U/mL) was added to the infinity 
reaction, and it was allowed to incubate for 30 minutes before quenching.  This timepoint 
served as a measure of complete fibrinopeptide release.  All samples were centrifuged for 15 
minutes at 4°C to spin down any clots that formed, and 200 µL of the supernatant was 
analyzed by HPLC (Shimazdu) on a Supelco Discovery C18 reverse phase column using the 
following gradient run at 1 mL/minute: 
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 0 – 1 minute   0% B 
 1 – 2 minutes   0 – 15% B 
 2 – 25 minutes  15 – 36% B 
 25 – 26 minutes  36 – 80% B 
 26 – 27 minutes  80 – 0% B 
 27 – 32 minutes  0% B 
Buffer A is 25 mM NaH2PO4/Na2HPO4 pH 6.0; buffer B is 50% acetonitrile in 25 mM 
NaH2PO4/Na2HPO4 pH 6.0 [12].  Elution positions of fibrinopeptide A and fibrinopeptide B 
were determined based on the elution profile of synthetic FpA and FpB standards.  The area 
under each peak of interest was integrated by Shimadzu’s Class-VP v. 5.03 data processing 
program. 
 Data is plotted as % fibrinopeptide released (setting 100% release from infinity 
timepoint) versus time.  k1, the first order rate constant for FpA release, is determined by 
fitting the FpA release curve as follows: 
 %FpA = (1 – e^(-k1t))*100 
k2 is the first order rate constant for FpB release after the release of FpA and is determined 
from the following equation: 
 %FpB = (1 + [k2/(k1 – k2)]e^(-k1t) – [k1/(k1 – k2)]e^(-k2t))*100 
For each fibrinopeptide, the specificity constant of thrombin for the fibrinopeptide is 
determined as shown: 
 kcat / KM = k(1 or 2) / [IIa] 
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Results 
Polymerization 
I measured polymerization by turbidity for 0.15 mg/mL recombinant γ/γ, γ′/γ′, and 
γ/γ′ fibrinogen at 1.0 nM thrombin with 10 µM, 2.0 mM, or 5.0 mM CaCl2.  Each variant was 
polymerized at each calcium concentration in three separate experiments.  As shown in 
Figure 3.1 A and B, γ′/γ′ fibrinogen displayed a longer lag time compared to γ/γ and γ/γ′ 
fibrinogen at 10 µM CaCl2.  This parameter was normalized at higher concentrations of 
calcium (Figure 3.1 C-F).  Lag times for γ/γ′ fibrinogen were the same as for γ/γ fibrinogen at 
each concentration of calcium.  The Vmax value, or maximal rate of polymerization, was 
lower for both γ′/γ′ and γ/γ′ fibrinogen at each concentration of calcium than it was for γ/γ 
fibrinogen.  Similarly, at each calcium concentration, the final absorbance of clots formed 
from fibrinogens containing a γ′ chain was lower than that of fibrinogens without a γ′ chain.  
In particular, γ′/γ′ fibrinogen displayed the lowest final absorbance, while γ/γ′ fibrinogen had 
a final absorbance that was intermediate between γ/γ and γ′/γ′.  
 Table 3.1 contains the values for lag time, maximal rate of polymerization, and final 
absorbance measured for each fibrinogen variant at three concentrations of calcium. 
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Figure 3.1.  Polymerization of recombinant γ/γ (blue), γ′/γ′ (green), and γ/γ′ (orange) 
fibrinogen at three concentrations of calcium, 0.01 mM (A,B), 2.0 mM (C,D), and 5.0 mM 
(E,F).  Polymerization was initiated by addition of 1.0 nM thrombin to 0.15 mg/mL 
fibrinogen, and monitored at 350 nm every 10 seconds for 90 minutes.  On the left are full 
polymerization curves (A,C,E); a close-up of the lag time is on the right (B,D,F).  Curves are 
the mean of 3 experiments.  Error bars indicate + or – 1 standard deviation. 
A B 
C D 
E F 
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Polymerization Parameters for γ /γ, γ′ /γ′, and γ /γ′  Fibrinogen 
Lag Time 
(seconds)       
  γ/γ Fibrinogen γ'/γ' Fibrinogen γ/γ' Fibrinogen 
0.010 mM CaCl2 117 +/- 12 175 +/- 7*   120 +/- 30  
2.0 mM CaCl2 100 +/- 20 97 +/- 12 83 +/- 25 
5.0 mM CaCl2 103 +/- 25 90 +/- 17 75 +/- 7 
        
Maximal Rate 
(milliunits/ 
minute)       
  γ/γ Fibrinogen γ'/γ' Fibrinogen γ/γ' Fibrinogen 
0.010 mM CaCl2 83 +/- 8 11 +/- 0.2* 26 +/- 6* 
2.0 mM CaCl2 108 +/- 7 19 +/- 4* 40 +/- 8* 
5.0 mM CaCl2 108 +/- 17 25 +/- 9* 50 +/- 0.2* 
        
Final 
Absorbance       
  γ/γ Fibrinogen γ'/γ' Fibrinogen γ/γ' Fibrinogen 
0.010 mM CaCl2 0.198 +/- 0.012 0.070 +/- 0.007* 0.140 +/- 0.017* 
2.0 mM CaCl2 0.231 +/- 0.014 0.097 +/- 0.021* 0.160 +/- 0.019* 
5.0 mM CaCl2 0.248 +/- 0.011 0.103 +/- 0.015* 0.169 +/- 0.013* 
 Table 3.1.  Parameters are listed for lag time, Vmax, and final absorbance for each fibrinogen 
at three concentrations of calcium.  * Indicates p values less than 0.05, indicating greater than 
95% probability of significant variation from γ/γ fibrinogen. 
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Fibrinopeptide Release 
 Fibrinopeptide release from fibrinogen γ′ variants was measured at 0.10 mg/mL 
fibrinogen and 0.10 nM (0.01 U/mL) thrombin.  Figure 3.2 shows the results of this 
experiment, and Table 3.2 shows the kinetic constants determined for each fibrinogen.  Data 
was fit to two sequential first-order rate equations as described in Methods.  The rate constant 
for FpA release was k1, and the specificity constant of thrombin for FpA was k1/KM.  Both 
γ′/γ′ and γ/γ′ fibrinogen released FpA at the same rate as did γ/γ fibrinogen.  Release of FpB 
from γ′/γ′, however, was faster compared to γ/γ or γ/γ′ fibrinogen, as shown by a greater rate 
constant for FpB release (k2).  The specificity constant for the thrombin FpB interaction 
(k2/KM) also increased for γ′/γ′ fibrinogen. 
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Figure 3.2.  Fibrinopeptide release monitored by HPLC from 0.10 mg/mL recombinant 
fibrinogen by addition of 0.10 nM thrombin.  FpA release in closed symbols and FpB release 
in open symbols from normal γ/γ fibrinogen (blue circles), γ′/γ′ fibrinogen (green squares), or 
γ/γ′ fibrinogen (orange diamonds).  The first 20 minutes of the reaction are shown in detail in 
the inset. 
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Fibrinopeptide Release Rate Constants 
  FpA   FpB   
Fibrinogen k1 (min
-1) k1/KM (s
-1M-1) k2 (min
-1) k2/KM (s
-1M-1) 
γ/γ 
0.071 +/- 
0.004 
1.2x107 +/- 
5.8x105 
0.045 +/- 
0.003 
7.8x106 +/- 
6.9x105 
γ'/γ' 
0.077 +/- 
0.005 
1.3x107 +/- 
5.8x105 
0.069 +/- 
0.006* 
1.2x107 +/- 
1.0x106* 
γ/γ' 
0.069 +/- 
0.004 
1.2x107 +/- 
5.8x105 
0.049 +/- 
0.003 
8.6x106 +/-
4.7x105 
Table 3.2.  k1 and k1/KM are rate constant and specificity constant for FpA release; k2 and 
k2/KM are rate constant and specificity constant for FpB release.  Values are shown +/- 
standard deviation from 3 experiments.  * indicates p values for comparison with normal γ/γ 
fibrinogen < 0.05, meaning > 95% probability of significant variation from γ/γ fibrinogen. 
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Discussion 
We measured polymerization by turbidity for recombinant γ/γ, γ′/γ′, and γ/γ′ 
fibrinogen at 10 µM, 2.0 mM, and 5.0 mM calcium.  Lag time comparison indicated that γ′/γ′ 
fibrinogen formed protofibrils significantly more slowly than γ/γ or γ/γ′ fibrinogen at 10 µM 
CaCl2.  Increasing the concentration of calcium to either 2.0 or 5.0 mM resulted in γ′/γ′ 
fibrinogen displaying a lag time similar to γ/γ fibrinogen.  These results suggest that γ′ chain 
homodimers impede protofibril formation in the absence of calcium, but the addition of 
calcium abrogates this effect. 
At each concentration of calcium investigated, both γ′ variants displayed statistically 
significant lower Vmax values compared to γ/γ fibrinogen. These observations demonstrate 
that the presence of the γ′ chain dramatically slows lateral aggregation during fiber 
formation. 
Similar to the pattern observed for Vmax values, the final absorbances of clots formed 
from either γ′/γ′ or γ/γ′ fibrinogens were decreased at each concentration of calcium 
compared to clots formed from γ/γ fibrinogen.  Because the final absorbance of a clot 
correlates with fiber thickness, we conclude that the presence of a γ′ chain decreases the 
diameter of fibers formed compared to those formed from γ/γ fibrinogen. 
 Weisel and Nagaswami’s kinetic model, described in the Introduction to this chapter, 
provides a framework to describe what may be taking place at a molecular level for each 
fibrinogen variant, and thus highlight the differences in polymerization caused by the 
presence of the γ′ chain [5].  At 2 mM CaCl2, close to physiological concentration of calcium, 
both γ′/γ′ and γ/γ′ fibrinogen displayed decreased final absorbance and Vmax, with a similar 
lag time compared to γ/γ fibrinogen.  The polymerization kinetic model suggests that this 
 77 
pattern of parameter changes is caused by an increase in the fiber initiation rate constant for 
these fibrinogens, and thus a decrease in the rate of lateral aggregation [5].  Such a decrease 
in lateral aggregation explains the diminished rate of polymerization as well as the presence 
of thinner fibers in γ′ clots.  The fibrinopeptide release results, however, showed that FpB 
was released more quickly from γ′/γ′ fibrinogen than from γ/γ fibrinogen.  This particular 
observation is not consistent with our model of decreased lateral aggregation and remains 
unexplained. 
 These data are not the first presented about the polymerization of γ′-chain containing 
fibrinogen.  Several reports have been published in recent years characterizing the 
polymerization behavior of γ/γ′ fibrinogen purified from plasma fibrinogen.  Our results may 
be compared with the previous studies, keeping in mind that we have studied recombinant 
fibrinogen while most previous work has employed plasma-derived protein.  Protein purified 
from plasma may always contain unidentified polymorphisms, variability in post-
translational processing, or significant and variable proteolytic degradation.  Recombinant 
protein, however, provides a population of protein with the exact mutation of interest. 
 In 2003, Cooper and coworkers published the results of a study of γ/γ′ fibrinogen 
separated from γ/γ fibrinogen by DE-52 ion-exchange chromatography of plasma fibrinogen 
[13].  At 10 mM CaCl2, they demonstrated a slower rate of polymerization and lower final 
absorbance for γ/γ′ fibrinogen compared to γ/γ fibrinogen with similar lag times between the 
two populations.  This result is very similar to our observations for γ/γ′ fibrinogen at 5 mM 
CaCl2.  From fibrinopeptide release experiments, they showed a similar rate of FpA release 
between the two populations, but found FpB to be released more slowly from γ/γ′ fibrinogen 
than from γ/γ fibrinogen [13].  We found no difference in FpB release between γ/γ and γ/γ′ 
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fibrinogen.  Notably, these studies were performed at significantly higher concentrations of 
fibrinogen, thrombin, and calcium than were ours which, along with the fact that they used 
plasma-derived protein and we studied recombinant fibrinogen, may help to explain the 
differences in fibrinopeptide release results.   
 In another study, Siebenlist and coworkers compared fibrinopeptide release for γ/γ′ 
fibrinogen compared to γ/γ fibrinogen.  They prepared γ/γ and γ/γ′ fibrinogen from DE-52 
chromatographed plasma fibrinogen and took a further step to remove factor XIII by 
ammonium-sulfate precipitation of the γ/γ′ fraction.  They found from this study that both 
FpA and FpB release are significantly delayed from γ/γ′ fibrinogen compared to γ/γ [14].  
These results are certainly inconsistent with both our results and those of Cooper et al [13].  
Again, they used significantly higher concentrations of fibrinogen and thrombin in these 
studies than we used in ours, but with no calcium, an essential cofactor, added to the reaction.  
It is also of concern that they performed an extra ammonium sulfate precipitation step on the 
γ/γ′ fibrinogen to remove factor XIII, but this step was not performed on the γ/γ sample.  
Perhaps a particular population of γ/γ′ fibrinogen was removed during this step leaving 
something less active in polymerization than would be the entire fraction of γ/γ′ fibrinogen. 
 Polymerization of recombinant γ′/γ′ fibrinogen has been studied by electron 
microscopy, but not by turbidity or fibrinopeptide release [15].  Recombinant γ/γ or γ′/γ′ 
fibrinogen expressed by BHK cells was clotted at 4.4 µM (1.5 mg/mL) with 5 mM CaCl2 and 
0.9 U/mL thrombin.  These clots were then analyzed by laser scanning confocal microscopy 
and scanning electron microscopy.  The structural differences between the two clots were 
small, with γ′/γ′ fibrinogen displaying 25% less densely packed and 7% thicker fibers [15].  
These differences were not statistically significant, however, and their variability from our 
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fiber thickness results may be explained by experimental differences between the use of 
turbidity versus electron microscopy for monitoring clot structure. 
 Comparison of our polymerization and fibrinopeptide release data with the results 
presented by others [13], [14], [15] suggests that the role of the γ′ chain in polymerization is 
complicated.  In our work with recombinant γ′ fibrinogen variants, we are sure of the 
presence of pure populations of both γ′/γ′ and γ/γ′ fibrinogen molecules.  There are no 
differences in post-translational modifications among recombinant proteins, nor do we have 
contamination from any other coagulation proteins.  Therefore, our observation that the 
presence of the γ′ chain in fibrinogen leads to decreased lateral aggregation is the best 
starting point for analysis of the role of the γ′ chain in polymerization. 
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FACTOR XIII BINDING TO FIBRINOGEN 
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Summary 
 In this chapter I have addressed the question of how factor XIII binds to fibrinogen 
when it is in both its zymogen form and its active form.  I measured binding to recombinant 
γ/γ fibrinogen, recombinant γ′/γ′ fibrinogen, recombinant γ/γ′ fibrinogen, recombinant Aα251 
fibrinogen, and plasma fibrinogen.  To quantitate binding, I developed both an ELISA assay 
with increasing concentrations of factor XIII binding to fibrinogen immobilized on a plate, as 
well as an immunoprecipitation assay in which I pull down fibrinogen and any factor XIII 
bound to it in solution.  Inhibition experiments show that soluble fibrinogen could prevent 
binding to immobilized fibrinogen in the ELISA assay.  The results of these experiments 
demonstrate that the γ′ chain plays no part in binding to either factor XIII zymogen or 
activated factor XIIIa. 
 
Introduction 
 Although some of the literature addressing the question of factor XIII binding to 
fibrinogen was discussed in the Introduction chapter of this document, I will present here a 
more complete overview of previous work.  The history of studies measuring factor XIII – 
fibrinogen interactions is filled with debate and controversy, and some of these unresolved 
conflicts are described below. 
Factor XIII Zymogen Binding to Fibrinogen 
 An early study of factor XIII binding to fibrinogen was undertaken by Greenberg and 
Shuman using 125I-labeled plasma or platelet factor XIII and fibrinogen coupled to latex or 
acrylonitrile beads.  Binding assays were performed by incubating the labeled factor XIII 
with the bead-coupled fibrinogen, and bound material was captured on a 0.4 µm filter.  
 84 
Radioactivity measured on the beads corresponded to bound factor XIII.  From this assay, a 
Kd for factor XIII zymogen binding to plasma fibrinogen was determined to be 1.4 +/- 0.06 x 
10-8 M, suggesting that factor XIII is bound to fibrinogen in plasma [1].  The concentration of 
factor XIII in plasma is about 0.15 µM [2], compared to around 7.5 µM fibrinogen [3]. 
 Following Greenberg and Shuman’s publication, a plethora of investigations by both 
the Greenberg and Shafer groups described the enhancement of factor XIII activation when it 
is bound to fibrin [4], [5], [6], [7], [8].  A kinetic study using HPLC of the release of FpA, 
FpB, and FXIII activation peptide indicated that AP release from factor XIII is faster when 
fibrinogen is included in the reaction mixture, and that FpA is likely cleaved before FXIII 
AP, suggesting that des-A fibrin is the true cofactor for FXIII activation [4].  Greenberg and 
Miraglia extended these observations by showing that polymerized fibrin was the actual 
species necessary for promoting FXIIIa formation [5].  They included the polymerization 
inhibitor GPRP with factor XIII, thrombin, and fibrinogen, and found the fibrinogen-
catalyzed rate enhancement for factor XIII activation disappeared [5].  Once polymerized 
fibrin is cross-linked by factor XIIIa, however, its catalytic effect toward factor XIII 
zymogen activation is lost.  The binding of factor XIII to fibrinogen and fibrinogen’s 
cofactor activity are proposed as a regulatory mechanism for factor XIIIa.  By binding to 
fibrinogen, the enzyme is localized to where it will be needed.  It is not activated efficiently 
until fibrin begins to polymerize, and is no longer activated once it has performed its function 
and fibrin is cross-linked [6]. 
 Another conclusion from the Greenberg and Shuman binding study is, however, more 
controversial.  In their bead-coupled fibrinogen plus 125I-FXIII binding assays, they 
demonstrated that unlabeled platelet factor XIII could compete away both platelet and plasma 
 85 
factor XIII binding to fibrinogen.  This observation led them to conclude that the fibrinogen – 
factor XIII interaction takes place through the A subunits of factor XIII [1].  They confirmed 
their observations in a later study using platelet-poor plasma.  When 125I-labeled platelet 
factor XIII was added to this plasma sample, 85% of it went into the pellet when fibrinogen 
was spun down after polymerization by protamine sulfate which causes polymerization in the 
absence of FpA or FpB cleavage.  The authors concluded from this finding that plasma factor 
XIII also binds to fibrinogen via the A subunits because platelet factor XIII can do so [9].  
While I have reservations about whether protamine sulfate polymerized fibrinogen has the 
same binding behavior as monomeric fibrinogen, I find the competition of platelet factor XIII 
with plasma factor XIII compelling evidence that there is some binding site available on the 
A subunits of factor XIII for fibrinogen. 
 In contrast to this finding, Hornyak and Shafer showed through elegant binding 
experiments in 1992 that, instead, the B subunits are responsible for binding to fibrinogen.  
They prepared active site blocked and radiolabeled carbamylmethyl forms of platelet factor 
XIII (A2) and factor XIIIa (A2ai).  They measured the binding of these forms of FXIII to 
fibrin II by adding acid-solubilized fibrin II to a solution of each, incubating for 30 minutes, 
and then spinning down the clot and measuring the amount of radioactivity incorporated into 
it.  Active-site inhibited FXIIIa (A2ai) bound fibrin with a Kd of 2.1 µM, while unactivated 
platelet FXIII (A2) had a Kd of 14 µM for fibrin.  Binding of factor XIII zymogen (A2B2) to 
fibrin, however, was much stronger than either of these interactions with a Kd of 0.20 µM.  In 
addition, factor XIII zymogen did not disrupt binding of FXIIIa to fibrin [10].  In contrast 
with Greenberg and Shuman’s conclusion that plasma and platelet factor XIII binding both 
occur through the A subunits and with the same dissociation constant, these findings show 
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that the B subunits of plasma factor XIII provide a high-affinity binding site for fibrin.  There 
are significant differences between these two studies such as the use of fibrinogen versus 
fibrin and the method used to detect binding, which may explain some of their differing 
conclusions. 
 Based on Hornyak and Shafer’s rigorous study, however, it has become generally 
accepted that factor XIII A subunits bind to fibrinogen at a different site than do factor XIII 
B subunits.  Procyk and coworkers localized the binding site for active factor XIIIa (A2a) to 
the C-terminal part of the Aα chain of fibrinogen using recombinant factor XIII which is 
composed of just A subunits.  They radiolabeled this factor XIII and measured the amount of 
buffer required for it to permeate through a fibrin clot formed in a small column.  These 
permeation experiments showed that unactivated rFXIII (A2) quickly percolated through the 
clot while rFXIIIa (A2a) took longer, suggesting that only the active form of the enzyme 
binds when B subunits are absent.  Treatment of the clot with an antibody to the C-terminal 
region of the Aα-chain blocked rFXIIIa binding to the clot, as did percolation of a fibrinogen 
fragment corresponding to Aα241-476 along with the rFXIIIa.  These results suggest that 
activated A subunits of factor XIII bind the αC domains of fibrinogen [11]. 
 Localization of the binding site on fibrinogen for factor XIII zymogen began with an 
immunoblotting study in 1987 in which intact fibrinogen or its fragments (X, D1, D2, D3, D-
dimer, and E) were run on reduced or non-reduced SDS-PAGE gels and transferred to 
nitrocellulose membranes.  These membranes were then incubated with factor XIII zymogen, 
washed, and probed with an anti-FXIII antibody to determine which fragments or chains of 
fibrinogen bound to factor XIII.  Results indicated that X, D1, D2, D3, and D-dimer, but not E 
fragment bound FXIII while Aα and Bβ chains, but not γ chain also bound FXIII [12].  The 
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blots shown in this paper are not very clear, and the results of this investigation have been 
mostly disregarded. 
 A more widely accepted study was published in 1996 by Siebenlist and coworkers.  
They observed that factor XIII co-purifies with the γ′ chain of fibrinogen, rather than with the 
γ chain, and suggested that the unique sequence at the C-terminus of this chain may provide a 
binding site for factor XIII zymogen.  When a mixture of γ/γ fibrinogen and factor XIII are 
separated by ion-exchange chromatography, they elute as two separate peaks with fibrinogen 
in the early peak and factor XIII in the later peak, as shown by a factor XIII activity assay of 
each fraction.  However, when γ/γ′ fibrinogen and factor XIII are mixed, they elute as a 
single peak much later than the peaks described above, with factor XIII activity found 
throughout the peak.  Size-exclusion chromatography gave similar results; individual peaks 
are observed with a mixture of γ/γ fibrinogen and factor XIII zymogen, while the factor XIII 
peak shifts up to the position of fibrinogen when mixed with γ/γ′ fibrinogen.  These studies 
suggest that the γ′ chain does, indeed, provide a binding site for factor XIII zymogen [13]. 
 To further characterize this binding site, Moaddel et al. measured the dissociation 
constant for FXIII-γ/γ fibrinogen complexes and FXIII-γ/γ′ fibrinogen complexes by 
analytical ultracentrifugation.  Both types of fibrinogen were purified from plasma.  They 
found an association constant for γ/γ fibrinogen + FXIII zymogen of 1.3 x 108M-2 and a 20-
fold stronger association constant for γ/γ′ fibrinogen + FXIII zymogen of 3.6 x 109M-2.  
Inclusion of a peptide mimicking the γ′ sequence in ultracentrifugation experiments 
confirmed that this region is responsible for the increased affinity [14].  Recently, however, 
the conclusions of this study have been called into question.  Because it has been shown that 
factor XIII zymogen can cross-link fibrinogen in the presence of physiological levels of 
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CaCl2, it is almost certain that such cross-linking took place during the extensive incubation 
of fibrinogen and factor XIII with 1mM CaCl2 in these ultracentrifugation experiments.  
Siebenlist and coworkers suggest that the noncovalent fibrinogen + FXIII complexes 
Moaddel’s group thought they were measuring in the analytical ultracentrifuge were, in fact, 
cross-linked fibrinogen molecules [15]. 
 I will contribute to this ongoing discussion about the role of the γ′ chain in factor XIII 
binding to fibrinogen by using recombinant fibrinogen variants.  These variants allow me to 
isolate the role of the γ′ chain with respect to factor XIII binding.  I have compared factor 
XIII binding to fibrinogen with two γ′ chains, one γ and one γ′, or two γ chains.  These three 
variants only differ in the presence of the γ′ chain; they will not display the variability present 
in any sample of fibrinogen isolated from a collection of human plasma.  Use of an ELISA to 
measure binding will remove from consideration the problem of fibrinogen cross-linking by 
factor XIII zymogen.  Instead of a two day incubation as was required in Moaddel’s 
ultracentrifuge experiments [14], the two proteins must only be incubated for an hour during 
an ELISA.  In addition, the fibrinogen is immobilized on the plate, thereby limiting the extent 
of cross-linking that may take place to only those molecules immobilized in direct contact 
with one another.  This format has allowed me to draw clear conclusions about the role of the 
γ′ chain in binding to factor XIII. 
 
Materials and Methods 
Materials.   
 Human plasma fibrinogen depleted of plasminogen, fibronectin, and factor XIII (lots 
030411 and 050518) was purchased from American Diagnostica (Stamford, CT).  Human 
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factor XIII (lots 850A and 3040P) and human α-thrombin (lot 2690PR) were purchased from 
Enzyme Research Laboratories (South Bend, IN).  Recombinant factor XIII was a kind gift 
from Dr. Rasmus Rojkjaer at Novo Nordisk (Princeton, NJ).  Hirudin (lot B68947) was 
obtained from Calbiochem (San Diego, CA).  Bovine serum albumin (lot 103161376) was 
purchased from Sigma-Aldrich (St. Louis, MO).  Antibodies 4A5, 2G2H9, Y-18, polyclonal 
anti-human fibrinogen, and HRP-conjugated goat anti-rabbit and anti-mouse were described 
in Chapter Two.  A monoclonal antibody to fibrinogen Bβ chain was a kind gift from Dr. 
John Shainoff (Cleveland State University, Cleveland, OH).  Sheep anti-factor XIII A-chain 
antibody (lotAP155-BR5) and HRP-conjugated donkey anti-sheep IgG (lot HAP1270-B121) 
were purchased from Affinity Biologicals (Ancaster, Ontario).  SureBlue peroxidase 
substrate was obtained from KPL (Gaithersburg, MD).  All chemicals were purchased from 
Fisher. 
Protein Preparation 
 Recombinant γ′/γ′ and γ/γ′ fibrinogen were expressed and purified as described in 
Chapter Two.  Normal, recombinant γ/γ fibrinogen and recombinant Aα251 fibrinogen in 
which the C-terminus of the Aα chain is truncated at residue 251 were prepared as described 
[16], [17] and purified as described [18].  Both fibrinogen (plasma and recombinant) and 
factor XIII (plasma and recombinant) were dialyzed extensively against 20 mM HEPES pH 
7.4, 150 mM NaCl (HBS). 
ELISA Binding Assay 
 Wells of a Corning half-area untreated microtiter plate were coated with 50 µL of 
0.029 µM fibrinogen diluted in HBS + 1 mM CaCl2 (HBS+Ca).  After one hour, this solution 
was removed and the plate was washed three times with 200 µL per well of HBS+Ca + 0.5% 
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Tween-20 (HBST+Ca).  All washes were performed in this manner.  In some assays, 
fibrinogen was converted to fibrin by addition of 50 µL of 1 U/mL human α-thrombin for 1 
hour, followed by washing, addition of 50 µL of 10 U/mL hirudin for 20 minutes, and 
another wash.  In all assays, fibrin(ogen) was blocked with 100 µL of 0.1% BSA in HBS+Ca 
(BSA/HBS+Ca) for 1 hour, followed by washing. 
 Active-site inhibited recombinant factor XIII (rFXIIIai) was prepared for some assays 
by diluting rFXIII to 20 µM in HBS + 10 mM CaCl2.  Human α-thrombin diluted in HBS+Ca 
was added to a final concentration of 32 U/mL, and the solution was incubated for 45 
minutes at 37°C to allow for factor XIII activation.  After activation, hirudin was added to 
320 U/mL to inhibit thrombin, and a final concentration of 20 mM iodoacetic acid was added 
to block the active site of recombinant factor XIII. 
 Serial dilutions of factor XIII (FXIII), unactivated recombinant factor XIII (rFXIII) or 
recombinant, activated, active-site inhibited factor XIII (rFXIIIai) were prepared in 50 µL in 
HBS+Ca ranging from 0.40 µM to 0.00040 µM FXIII, 5.0 – 0.050 µM rFXIII, or 0.80 to 
0.00080 µM rFXIIIai.  These serial dilutions were added to wells 1 – 11 of the fibrinogen-
coated microtiter plate, and 50 µL of HBS+Ca was added to well 12.  After 1 hour of 
incubation, the factor XIII was removed, and the plate was washed.  50 µL of anti-factor XIII 
antibody diluted 1:3000 in BSA/HBS+Ca was added to each well for one hour and washed.  
HRP-conjugated donkey anti-sheep antibody was diluted 1:10000 in BSA/HBS+Ca and 50 
µL was added to each well for 1 hour followed by removal and three washes.  The plate was 
developed with 50 µL of Sure Blue peroxidase substrate and fixed with 50 µL of 1 M 
phosphoric acid.  Absorbance was measured at 450 nm on a SpectraMax 340PC microtiter 
plate reader. 
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γ and γ′ Chain Accessibility ELISA 
 Serial dilutions of recombinant γ/γ or γ′/γ′ fibrinogen were prepared in 50 µL of 
HBS+Ca from 100 µg/mL to 0.098 µg/mL and placed in wells 1 – 11 of a microtiter plate 
with 50 µL of HBS+Ca in well 12.  After 1 hour of incubation, the plate was washed three 
times with HBST+Ca and blocked with BSA/HBS+Ca as described above.  It was probed 
with 1:5000 4A5 or 1:1000 2G2H9, followed by 1:5000 HRP-conjugated goat anti-mouse 
secondary antibody, all diluted in BSA/HBS+Ca.  The plate was developed as described 
above. 
Inhibition by Soluble Fibrinogen 
 Microtiter plates were coated with plasma or recombinant fibrinogen and blocked as 
described above.  Thirty minutes before addition to the plate, 0.10 µM FXIII or rFXIIIai was 
mixed with an equal volume of plasma fibrinogen serial dilutions in 0.1% BSA in HBS+Ca.  
The final concentration of (r)FXIII(ai) was 0.050 µM and fibrinogen inhibitor concentrations 
ranged from 9.0 to 0.56 µM.  One well contained 0.050 µM (r)FXIII(ai) with no inhibitor; 
another well contained buffer only.  These mixtures were incubated on the microtiter plate 
for 1 hour, and the plate was exposed to antibody and developed as described above. 
Immunoprecipitation Binding Assay  
Plasma, recombinant γ/γ, or recombinant γ′/γ′ fibrinogen (0.29 µM) and factor XIII 
(serial dilutions from 0.80 – 0.025 µM) were incubated in 25 µL for one hour at room 
temperature.  Y-18 sepharose beads were prepared according to the protocol described in 
Chapter Two for 4A5 beads.  20 µL of these beads were added to each reaction mixture and 
rotated for 2 hours at 4°C.  Unbound factor XIII was removed by four 1-mL washes with 50 
mM Tris pH 7.4, 300 mM NaCl, 0.1% TritonX-100, 0.05% Tween-20.  The beads were 
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washed once more with HBS, and then all supernatant was removed.  Beads were redissolved 
in 15 µL HBS + 4 µL 6X Laemmli buffer + 2 µL BME.  These samples were run in duplicate 
on 11% gels and transferred to nitrocellulose.  Along with them I ran a standard curve of 
each fibrinogen and a standard curve of factor XIII.  One blot of each set was developed with 
a mixture of 1:5000 anti-Bβ chain and 1:4000 anti-FXIII A chain followed by 1:5000 HRP 
anti-mouse and 1:5000 HRP anti-sheep; the other was developed with 1:5000 DAKO 
polyclonal anti-fibrinogen and 1:5000 HRP anti-rabbit.  Western blots were scanned and 
analyzed by densitometry.  The concentrations of fibrinogen Bβ chain and factor XIII in each 
sample were determined by comparison to the fibrinogen and factor XIII standard curves.  A 
binding curve was constructed by plotting the ratio of FXIII/fibrinogen (the concentration of 
FXIII brought down in each sample divided by the concentration of fibrinogen in that 
sample, as determined from the standard curve) versus the concentration of FXIII added to 
the sample. 
 
Results 
Measuring Factor XIII Binding to Fibrinogen 
 I developed an ELISA-type assay to determine Kd values for factor XIII binding to 
fibrinogen.  In this assay, I immobilized fibrinogen variants on a microtiter plate, blocked 
with BSA, and added a range of concentrations of factor XIII, in the presence of 1 mM 
CaCl2.  These proteins incubated for an hour, and then I washed the plate and probed for 
factor XIII that remained bound to the fibrinogen with a primary antibody for factor XIII 
followed by an HRP-conjugated secondary antibody.  I constructed binding curves by 
plotting the absorbance at 450 nm for each well versus the concentration of factor XIII 
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originally added to that well.  Fitting the data to the binding equation shown below generated 
Kd values: 
 y = [(Binding Max) * x] / [x + Kd] 
This equation also provides the absorbance that corresponds to maximal binding.  However, 
the actual absorbance of any well depends upon not only the concentration of factor XIII 
present in that well, but also the precision with which antibody was diluted on that particular 
day, how fresh the chromogenic substrate was and therefore how quickly color developed, 
and at what stage of color development I quenched the reaction.  Because the maximal 
absorbance did not relate to any single physical quantity, I chose to divide the absorbance 
measurements that composed each binding curve by the maximal absorbance determined in 
the equation above.  Doing so generated a binding ratio, a measurement of the amount of 
factor XIII bound at any point divided by the maximal amount of factor XIII that could bind.  
No binding corresponded to 0, while maximal binding equaled 1.  By converting absorbance 
data into this binding ratio, I was able to plot binding curves measured on different days on 
the same scale.  This manipulation did not affect the Kd determined for each binding curve. 
 Factor XIII zymogen, a heterotetramer of two A and two B subunits, has been 
proposed to bind to the γ′ chain of fibrinogen [13].  If this hypothesis is true, then factor XIII 
should have a stronger Kd for binding recombinant γ′/γ′ and γ/γ′ fibrinogen than it does for 
recombinant γ/γ fibrinogen which doesn’t have a γ′ chain.  To ensure that recombinant 
fibrinogen behaves similarly to plasma fibrinogen, I have included plasma fibrinogen in each 
binding experiment.  Because it has been suggested that factor XIIIa (A subunits only) binds 
to the αC domains of fibrinogen [11], I have also studied the binding of factor XIII zymogen 
to recombinant Aα251 fibrinogen.  This fibrinogen is truncated at residue 251 of the Aα 
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chain and lacks αC domains.  It was used as a control to show that αC domains are not 
involved in the binding of factor XIII zymogen to fibrinogen. 
 The binding curves for factor XIII zymogen binding to plasma, recombinant γ/γ, 
recombinant Aα251, recombinant γ′/γ′, and recombinant γ/γ′ fibrinogens as well as bovine 
serum albumin are shown in Figure 4.1.  Very little difference existed between the curves, 
either at the low concentration points as shown in the inset, or at higher FXIII concentrations, 
as shown in the main figure.  As shown in Table 4.1, the Kd values were, within error, the 
same for each fibrinogen variant, and around 0.04 µM.  The black X data points in Figure 4.1 
correspond to factor XIII incubated with BSA immobilized on the microtiter plate.  Because 
no significant binding occurred to the BSA, we concluded that the binding curves shown are 
fibrinogen specific. 
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Figure 4.1.  Binding of factor XIII zymogen to fibrinogen variants as measured by ELISA.  
Fibrinogen variants (0.029 µM) or BSA were immobilized on a microtiter plate and blocked 
with BSA.  A range of factor XIII concentrations were added (0.0040 – 0.40 µM), incubated 
for 1 hour, and washed off.  Factor XIII that remained bound to the immobilized fibrinogen 
was quantitated by ELISA.  Data is plotted as binding ratio (absorbance at a particular point 
divided by maximal absorbance of the curve) versus concentration of FXIII added.  
Fibrinogens immobilized are shown in the legend.  Inset shows detail of the lower 
concentration region of the graph, from 0 – 0.050 µM factor XIII. 
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Factor XIII Binding to Fibrin(ogen) 
Fibrin(ogen) FXIII 
Kd 
(uM) 
Standard 
Deviation P Value     
        
(compared 
to γ/γ)     
plasma fgn FXIII 0.043 0.016 0.42     
γ/γ fgn FXIII 0.041 0.013       
γ'/γ' fgn FXIII 0.047 0.027 0.33     
γ/γ' fgn FXIII 0.040 0.020 0.45     
Aα251 fgn FXIII 0.040 0.017 0.43     
Fibrin(ogen) FXIII 
Kd 
(uM) 
Standard 
Deviation P Value P Value   
        
(compared 
to γ/γ) 
(compared to 
fgn + FXIII)   
plasma Fn FXIII 0.025 0.008 0.12 < 0.05   
γ/γ Fn FXIII 0.018 0.003   < 0.05   
γ'/γ' Fn FXIII 0.021 0.002 0.10 0.08   
γ/γ' Fn FXIII 0.021 0.002 0.20 0.13   
Aα251 Fn FXIII 0.034 0.020 0.12 0.32   
Fibrin(ogen) FXIII 
Kd 
(uM) 
Standard 
Deviation P Value P Value   
        
(compared 
to γ/γ) 
(compared to 
fgn + FXIII)   
plasma Fgn rFXIII 1.1 0.4 0.33 < 0.05   
γ/γ Fgn rFXIII 1.2 0.4   < 0.05   
γ'/γ' Fgn rFXIII 1.0 0.3 0.26 < 0.05   
γ/γ' Fgn rFXIII 1.2 0.7 0.48 < 0.05   
Aα251 Fgn rFXIII 1.2 0.3 0.47 < 0.05   
Fibrin(ogen) FXIII 
Kd 
(uM) 
Standard 
Deviation P Value P Value   
        
(compared 
to γ/γ) 
(compared to 
fgn + FXIII)   
plasma Fgn rFXIIIai 0.032 0.018 0.38 0.14   
γ/γ Fgn rFXIIIai 0.030 0.009   0.05   
γ'/γ' Fgn rFXIIIai 0.029 0.007 0.48 0.16   
γ/γ' Fgn rFXIIIai 0.029 0.007 0.48 0.21   
Aα251 Fgn rFXIIIai 0.035 0.020 0.31 0.35   
Fibrin(ogen) FXIII 
Kd 
(uM) 
Standard 
Deviation P Value P Value P Value 
        
(compared 
to γ/γ) 
(compared to 
fn + FXIII) 
(compared to 
fgn + rFXIIIai) 
plasma Fn rFXIIIai 0.012 0.006 0.34 < 0.05 < 0.05 
γ/γ Fn rFXIIIai 0.014 0.006   0.22 < 0.05 
γ'/γ' Fn rFXIIIai 0.011 0.004 0.23 < 0.05 < 0.05 
γ/γ' Fn rFXIIIai 0.018         
Aα251 Fn rFXIIIai 0.020 0.013 0.33 0.17 0.37 
 
Table 4.1.  Kd values for factor XIII binding to fibrinogen and fibrin.  Student’s t-tests are 
used to determine p values for comparison among variants or from one set of reactants to 
another.  P values less than 0.05 are highlighted in red, indicating a greater than 95% 
probability that the difference is significant. 
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To show whether the γ′ chain was accessible to factor XIII when fibrinogen was 
immobilized on an ELISA plate, I performed an ELISA assay with 2G2H9, an anti-γ′ C-
terminus antibody, as well as a control experiment with 4A5, an anti-γ chain C-terminus 
antibody.  I prepared serial dilutions of recombinant γ′/γ′ or γ/γ fibrinogen and used each to 
coat two rows of an ELISA plate.  After blocking with BSA, I developed one row of each 
fibrinogen with each antibody.  Figure 4.2a shows that probing with the anti-γ chain 
antibody, 4A5, generated a dose-dependent curve up to the point of saturation for γ/γ 
fibrinogen, but that there was very little reaction with γ′/γ′ fibrinogen.  Similarly, as shown in 
Figure 4.2b, when anti-γ′ antibody (2G2H9) was used, it recognized γ′/γ′ fibrinogen in a 
dose-dependent manner, but did not react with γ/γ fibrinogen.  These results show that when 
fibrinogen is immobilized, both the γ and the γ′ chain C-termini are accessible.  Thus, the C-
terminus of the γ′ chain, the proposed factor XIII zymogen binding site, is available for 
binding to factor XIII in the ELISA assay. 
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Figure 4.2.  A) Fibrinogen (γ/γ or γ′/γ′) was immobilized on an ELISA plate and probed with 
4A5, an anti-γ chain C-terminus antibody.  The γ/γ fibrinogen is recognized in a dose-
dependent manner, while very little antibody binds to γ′/γ′ fibrinogen.  B) The same 
fibrinogens are immobilized, but probed with 2G2H9, an anti-γ′ chain antibody.  In this 
situation, the γ′/γ′ fibrinogen is recognized in a dose-dependent fashion while virtually no 
antibody binds to γ/γ fibrinogen. 
A 
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 I performed inhibition experiments with soluble plasma fibrinogen to confirm the 
results of my ELISA binding experiments.  I coated an ELISA plate with variant fibrinogens 
and blocked as described, but then incubated 0.050 µM factor XIII with varying 
concentrations of plasma fibrinogen in 0.1% BSA for 30 minutes before addition to the 
ELISA plate, then probed with an anti-factor XIII antibody.  To determine the ratio of factor 
XIII bound at each concentration of inhibiting fibrinogen, I divided the absorbance at that 
point by the total absorbance for 0.050 µM factor XIII binding when no inhibitor is present.  
This calculation left me with the percentage of total factor XII bound at each point, expressed 
as a decimal.  I plotted this value versus the concentration of fibrinogen added as inhibitor, 
and fit the data to the following equation for exponential decay: 
 y = a + b*exp(-c*x) 
where a = the percentage of factor XIII binding that corresponds to maximum inhibition 
 b = the span of inhibition that can take place 
 c = EC50 value for the inhibitor 
 The results of the inhibition experiments for factor XIII zymogen binding to 
fibrinogen variants are shown in Figure 4.3 and Table 4.2.  Factor XIII was inhibited from 
binding to each of the fibrinogen variants by approximately the same concentration of plasma 
fibrinogen, as expected from the similar Kd values for each variant fibrinogen.  Notably, none 
of the variants displayed complete inhibition of factor XIII binding, even at 9 µM fibrinogen 
inhibitor.  One possible explanation for this phenomenon was that the large concentration of 
fibrinogen present in the fibrinogen + factor XIII mixture bound to the immobilized 
fibrinogen and kept any factor XIII bound to it present in the well, even though it was not 
directly interacting with the original immobilized layer. 
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Figure 4.3.  Inhibition of factor XIII binding to immobilized fibrinogen variants by soluble 
plasma fibrinogen.  ELISA plates were coated with the fibrinogen variants listed in the 
legend, blocked with BSA, then incubated with 0.050 µM FXIII mixed with 0.56 – 9.0 µM 
plasma fibrinogen, washed, and probed for bound factor XIII.  Absorbance at each point was 
divided by absorbance in the absence of inhibitor to generate % factor XIII bound, expressed 
as a decimal. 
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Inhibition of Factor XIII Binding to Immobilized Fibrinogen by Soluble Plasma 
Fibrinogen 
Immobilized 
Fibrinogen IC50 (µM) 
Standard 
Deviation P Value 
      
(compared to 
γ/γ) 
plasma 0.46 0.18 0.48 
γ/γ 0.47 0.16   
γ'/γ' 0.53 0.07 0.30 
γ/γ' 0.56     
Aα251 0.52 0.08 0.34 
 
Table 4.2.  IC50 values for plasma fibrinogen inhibition of factor XIII binding to the 
immobilized fibrinogen variants listed in the table.  IC50 values were determined from the 
equation y = a + b*exp(-c*x); where a = the percentage of factor XIII binding that 
corresponds to maximum inhibition, b = the span of inhibition that can take place, and c = 
EC50 value for the inhibitor.  Because it displayed similar results to γ′/γ′ fibrinogen, 
experiments were performed only once for γ/γ′ fibrinogen, and therefore have no standard 
deviation or p values. 
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 To further confirm the ELISA assay data, I developed another technique to use for 
measuring binding of factor XIII to fibrinogen.  This technique made it possible to measure 
binding in solution, rather than to immobilized fibrinogen.  I incubated 0.29 µM fibrinogen 
(plasma, recombinant γ/γ, or recombinant γ′/γ′) with 0.025 – 0.80 µM factor XIII zymogen in 
a series of Eppendorf tubes for one hour.  This concentration of fibrinogen was determined 
by control experiments so it would not be a limiting factor in the reaction.  I added Y-18 
conjugated sepharose beads and rotated for two hours to immunoprecipitate fibrinogen 
through binding of fibrinogen E regions to Y-18.  I washed the beads to remove unbound 
protein and then boiled them in reducing buffer and ran the samples out on an 11% gel.  I 
transferred to nitrocellulose and probed with a mixture of fibrinogen anti-Bβ chain antibody 
and anti-factor XIII A chain antibody.  The ratio of factor XIII to fibrinogen in each sample 
was determined by densitometry and a standard curve composed of known concentrations of 
fibrinogen or factor XIII run on the gel.  I then plotted this ratio versus the concentration of 
factor XIII added to the sample to generate a binding curve. 
 Figure 4.4 A shows a representative Western blot used for quantification of FXIII 
versus fibrinogen Bβ chain for each fibrinogen variant.  The lane on the left of each variant’s 
samples is the highest concentration of factor XIII, with concentrations decreasing to the 
right. Figure 4.4 B shows the samples used to construct standard curves for fibrinogen and 
factor XIII.  This data was then translated into binding curves as shown in Figure 4.5.  Fitting 
these curves to the binding equation yielded different maximal binding ratios, but a similar 
Kd for each variant.  The similar Kd for plasma, γ/γ, and γ′/γ′ fibrinogen was consistent with 
the results of the ELISA experiments.   
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 A 
 
 B 
 
Figure 4.4.  A) Western blot of factor XIII + fibrinogen immunoprecipitation reactions, 
developed with anti-fibrinogen Bβ chain and anti-factor XIII antibodies.  Locations of factor 
XIII and fibrinogen Bβ chain are marked on the right.  Equal concentrations of each 
fibrinogen are mixed with a range of concentrations of factor XIII zymogen prior to 
immunoprecipitation.  The concentrations of factor XIII originally added to the samples are 
listed above each well.  B) Western blot of fibrinogen and factor XIII standard curves 
developed with the same antibody solutions used in A.  Concentrations of fibrinogen and 
factor XIII are listed above each well.  Densitometry was used to measure the intensity of 
each band, and standard curves were prepared.  The concentration of fibrinogen and factor 
XIII in each sample well was determined from these curves. 
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Figure 4.5.  Binding curves constructed from an immunoprecipitation binding assay.  
Densitometry of Western blots and correlation with a standard curve for each protein were 
used to determine the ratio of factor XIII (µM) to fibrinogen (µM) pulled down in each 
sample.  This ratio was plotted versus the concentration of factor XIII present during the IP.  
Kd values are listed for a representative experiment. 
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 The Kd values calculated from Figure 4.5 are about five times weaker than those 
calculated from ELISA binding curves.  While this decrease may be due to differences in 
binding to fibrinogen in solution versus fibrinogen immobilized on a plate, it may also have 
its origins in the construction of the immunoprecipitation experiment.  It was difficult to 
determine whether Y-18 sepharose beads were able to pull down the large fibrinogen + factor 
XIII complex with the same ease as they would unbound fibrinogen.  This assay contained 
significant variability, inherent in the nature of Western blotting, development by 
chemiluminescence, and densitometry.  These variables led to the calculation of different 
maximum binding ratios each time the experiment was performed.   However, the general 
trend is clear.  In solution there was no difference in the affinity of factor XIII for fibrinogen 
that contains γ′ chains and fibrinogen that does not.  The consistency of this experiment with 
the ELISA results for the same proteins showed that the ELISA format provided a relevant 
approximation of binding in solution. 
Measuring Factor XIII Binding to Fibrin 
 I repeated the ELISA binding assay with fibrin to compare its binding to factor XIII 
with that of fibrinogen.  After coating the plate with fibrinogen, I washed off excess 
fibrinogen and incubated with 1.0 U/mL thrombin for an hour, followed by 10 U/mL hirudin 
to inactivate the thrombin, then washed and blocked with BSA.  I carried out the rest of the 
assay as described for fibrinogen.  Binding curves for factor XIII binding to fibrin variants 
are shown in Figure 4.6a and Kd values are listed in Table 4.1.  As discovered for factor XIII 
binding to fibrinogen, there was no significant difference among the Kds for factor XIII 
binding to any of the fibrin variants. 
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 Figure 4.6b is an overlay of the factor XIII binding curves for fibrinogen and fibrin, 
with only γ/γ, γ′/γ′, and Aα251 fibrinogen shown for clarity.  This plot shows that factor XIII 
binding to γ/γ or γ′/γ′ fibrin was stronger than factor XIII binding to γ/γ fibrinogen (p < 0.05) 
or γ′/γ′ fibrinogen (p = 0.05).  Although not statistically significant for γ/γ′ or Aα251 fibrin, a 
similar trend existed for each fibrinogen variant (see Table 4.1). 
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Figure 4.6.  A)  Factor XIII binding to fibrin variants.  An ELISA assay was performed as 
described above, after converting immobilized fibrinogen to fibrin with 1.0 U/mL thrombin 
followed by 10 U/mL hirudin.  The inset shows the low concentration points on the binding 
curve.  B) Overlay of factor XIII binding to γ/γ, γ′/γ′, and Aα251 fibrinogen with factor XIII 
binding to γ/γ, γ′/γ′, Aα251 fibrin.  Fibrin binding curves are shown with open symbols and a 
broken curve fit while fibrinogen binding curves are shown with closed symbols and a solid 
fit.  The inset shows the low concentration points on the binding curve. 
A 
B 
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Recombinant Factor XIII Binding to Fibrinogen 
 Next, I performed ELISA binding experiments using recombinant factor XIII which 
is composed of only the A subunits.  These experiments were set up using the same protocols 
as those for factor XIII zymogen; the only difference was that concentrations up to 5.0 µM 
rFXIII were used to generate binding curves.  These curves are shown in Figure 4.7 for 
plasma fibrinogen, each of the recombinant fibrinogens, and BSA as a control.  Once again, 
since little or no binding occured on wells coated with BSA, binding to these fibrinogen 
variants was specific.  Like factor XIII zymogen, recombinant factor XIII bound with equal 
affinity to each recombinant fibrinogen, suggesting that neither the γ′ chain nor the αC 
domain is responsible for binding to the unactivated A subunits of factor XIII.  Kds for rFXIII 
binding to fibrinogen are listed in Table 4.1.  These values were all significantly weaker than 
the Kds for factor XIII zymogen binding to fibrinogen. 
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Figure 4.7.  Recombinant factor XIII (rFXIII) binding to fibrinogen variants listed in the 
legend.  ELISA plates were coated with each fibrinogen, blocked with BSA, incubated with 
recombinant factor XIII, and probed for rFXIII that remained bound after washing.  
Absorbance data was analyzed as described for Figure 4.1. 
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Recombinant, Activated Factor XIII Binding to Fibrinogen 
 In order to compare the binding sites on fibrinogen for factor XII in its active form to 
its zymogen state, I activated recombinant factor XIII using 32 U/mL thrombin and 
incubating at 37°C for 45 minutes.  After the rFXIII had become active, I quenched the 
thrombin with 320 U/mL hirudin and blocked the active site of rFXIIIa with 20 mM 
iodoacetic acid.  The iodoacetic acid forms a bond with the active site sulfhydryl group, 
effectively blocking rFXIIIa activity.  Figure 4.8 is an SDS-PAGE gel of recombinant factor 
XIII in various stages of activation incubated with recombinant γ/γ fibrinogen for 1 hour.  
Lane 4 of this gel shows that active-site inhibited, activated recombinant factor XIIIa 
(rFXIIIai) did not cross-link fibrinogen to any extent while rFXIIIa did so extensively.  Thus, 
the rFXIIIai used in the ELISA binding experiments was fully inhibited. 
Binding experiments with rFXIIIai binding to fibrinogen were performed much as 
described for factor XIII zymogen and rFXIII, except that the highest concentration of 
rFXIIIai used was 0.80 µM.  Binding curves for rFXIIIai binding to fibrinogen variants are 
shown in Figure 4.9 with the inset displaying an enlarged view of the low rFXIIIai 
concentration points.  This plot shows that neither the presence of the γ′ chain nor the loss of 
the αC domains had an effect on activated factor XIII binding to fibrinogen.  Kd values are 
listed in Table 4.1. 
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Figure 4.8.  Coomassie-stained 11% SDS-PAGE of γ/γ fibrinogen (lane 1), γ/γ fibrinogen 
incubated with rFXIII for 1 hour (lane 2), γ/γ fibrinogen incubated with rFXIIIa for 1 hour 
(lane 3), and γ/γ fibrinogen incubated with rFXIIIai for 1 hour (lane 4).  Samples were 
prepared from 0.30 mg/mL fibrinogen and 0.80 µM rFXIII(a)(i), and were quenched with 
Laemmli buffer and reduced with BME. 
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Figure 4.9.  Binding curves for ELISA binding assay of rFXIIIai binding to fibrinogen 
variants.  Experiments were performed and data processed as described in the legend for 
Figure 4.1.  Inset shows detail of the rFXIIIai concentrations from 0 – 0.10 µM. 
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 To confirm that there was no difference in rFXIIIai binding to any of the fibrinogen 
variants, I performed inhibition experiments as described for factor XIII zymogen.  Briefly, I 
incubated 0.050 µM rFXIIIai for 30 minutes with varying concentrations of plasma 
fibrinogen before addition to fibrinogen-coated ELISA wells.  Results of these inhibition 
experiments are shown in Figure 4.10.  Plasma fibrinogen inhibited rFXIIIai binding to each 
of the fibrinogen variants to relatively the same extent, and each of the variants retained 
approximately 50% binding, even at high concentrations of fibrinogen inhibitor.  Table 4.3 
lists the IC50 values for plasma fibrinogen inhibiting binding to each fibrinogen variant and 
shows that there is no statistical difference in ease of inhibition among variants.   
 114 
0.0
0.20
0.40
0.60
0.80
1.0
0.0 2.0 4.0 6.0 8.0 10
Plasma Fgn
!/! Fgn
!'/!' Fgn
!/!' Fgn
A"251 Fgn
%
 r
F
X
II
Ia
i 
B
o
u
n
d
[Fibrinogen] (µM)
 
Figure 4.10.  Inhibition of rFXIIIai binding to immobilized fibrinogen variants by plasma 
fibrinogen in solution.  Experiments were performed and data analyzed as described in the 
legend of figure 4.3, except that rFXIIIai was used, rather than FXIII zymogen. 
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Inhibition of rFXIIIai Binding to Fibrinogen Variants by Plasma Fibrinogen in 
Solution 
Immobilized 
Fibrinogen IC50 (µM) 
Standard 
Deviation P Value 
      (compared to γ/γ) 
plasma 0.47 0.11 0.43 
γ/γ 0.48 0.09   
γ'/γ' 0.52 0.34 0.43 
γ/γ' 0.62 0.09 0.08 
Aα251 0.51 0.07 0.33 
 Table 4.3.  Inhibition data was fit to the equation y = a + b*exp(-c*x), as described in the 
legend of Table 4.2.  P values were determined by a Student’s t-test. 
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Recombinant, Activated Factor XIII Binding to Fibrin 
 I converted the fibrinogen layer coating an ELISA plate to fibrin using 1.0 U/mL 
thrombin incubation for 1 hour, followed by treatment with 10 U/mL hirudin for 10 minutes, 
and then added rFXIIIai as described for fibrinogen binding assays.  Binding curves are 
shown in Figure 4.11 A and B.  rFXIIIai bound to each fibrin variant, within error, with the 
same affinity (Figure 4.11 A).  Table 4.1 shows that rFXIIIai generally bound fibrin more 
tightly than factor XIII zymogen bound fibrin; this trend was significant for plasma and γ′/γ′ 
fibrinogen.  Figure 4.11 B indicates that for γ/γ, γ′/γ′, and Aα251 fibrinogen, the binding of 
rFXIIIai to fibrin was significantly tighter than rFXIIIai binding to fibrinogen.  A similar 
trend holds true for plasma and γ/γ′ fibrinogen, not shown in the figure for clarity. 
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Figure 4.11.  A) Binding curves for rFXIIIai binding to fibrin variants.  Inset shows binding 
to low concentrations of rFXIIIai.  B) Comparison of binding curves for rFXIIIai binding to 
fibrinogen (filled symbols and solid lines) versus fibrin (open symbols and dashed lines).  
Inset shows low concentrations of rFXIIIai.  For simplicity, only γ/γ, γ′/γ′, and Aα251 
fibrinogens are shown.  Other variants display the same pattern. 
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Discussion 
 The experiments presented in this work show, unequivocally, that the γ′ chain of 
fibrinogen is not involved in binding to factor XIII zymogen.  Antibody recognition 
experiments showed that the C-terminus of the γ′ chain was accessible when γ′/γ′ fibrinogen 
was immobilized on a microtiter plate.  However, when measured by ELISA, the binding 
curve for factor XIII zymogen binding to immobilized γ/γ fibrinogen overlapped the binding 
curves for γ′/γ′ fibrinogen, γ/γ′ fibrinogen, and even plasma fibrinogen which contains ~90% 
γ/γ molecules and ~10% γ/γ′ molecules.  Thus, there ias no enhancement for factor XIII 
binding to a fibrinogen variant with a γ′ chain present compared to binding to γ/γ fibrinogen.  
The Kd determined for plasma fibrinogen binding to factor XIII zymogen was 0.043 +/- 
0.016 µM, on the same order as the 0.01 µM Kd reported by Greenberg and Shuman [1]. 
The results of the ELISA binding experiments are supported by inhibition 
experiments in which binding of factor XIII zymogen to fibrinogen on the ELISA plate is 
inhibited by fibrinogen in solution.  Within error, the same concentration of fibrinogen in 
solution was required to achieve 50% inhibition of factor XIII binding to each of the 
fibrinogen variants, whether or not they contained a γ′ chain.  This finding that the γ′ chains 
are not implicated in factor XIII binding is not just an artifact of the ELISA system.  Kd 
values determined by mixing fibrinogen and factor XIII in solution followed by 
immunoprecipitation of fibrinogen and any bound factor XIII demonstrated the same pattern; 
that the presence of the γ′ chain did not influence the Kd of factor XIII zymogen binding to 
fibrinogen. 
 This conclusion is in direct conflict with the work of Siebenlist, Meh, and Mosesson, 
as well as with Moaddel, Farrell, Daugherty, and Fried [13], [14].  Moaddel and coworkers 
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performed analytical ultracentrifugation experiments to compare the Ka for factor XIII 
zymogen binding to plasma γ/γ fibrinogen with that of plasma γ/γ′ fibrinogen [14].  While 
they found an enhanced association between γ/γ′ fibrinogen and factor XIII compared to γ/γ 
fibrinogen, these results have recently been called into question by the finding that factor 
XIII zymogen is capable of cross-linking fibrinogen prior to activation by thrombin, 
particularly over the long incubation period required for the analytical ultracentrifuge 
experiments [15].  In support of their assertions, however, Moaddel et al. also performed an 
ultracentrifuge experiment in which they included a 20-amino acid polypeptide of the γ′ 
sequence and found that this peptide was capable of inhibiting fibrinogen binding to factor 
XIII [14].  While this experiment lends more credence to the hypothesis that γ′ binds factor 
XIII since the peptide was not subject to cross-linking by factor XIII, it is by no means proof 
of a high affinity γ′ site.  Rather high concentrations of peptide were required for inhibition 
(approximately 100 µM), and control experiments mixing this peptide with γ/γ fibrinogen to 
check for nonspecific inhibition were never reported. 
 Siebenlist et al. demonstrated factor XIII binding to plasma γ/γ′ fibrinogen rather than 
γ/γ fibrinogen by ion-exchange and size-exclusion chromatography [13].  Using an identical 
column set-up, I was unable to replicate their size-exclusion chromatography results (data not 
shown).  One step that I omitted which they performed for both these experiments and the 
ion-exchange studies was to dialyze the fibrinogen and factor XIII after mixing them 
together.  Because I was concerned with zymogen-catalyzed cross-linking, I simply dialyzed 
the two proteins into the same buffer individually, then incubated them for 15 minutes, rather 
than a (presumably) overnight dialysis.  Both my observations described in the Appendix to 
this document as well as the authors’ own later publication [15] indicate that such a dialysis 
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period would lead to a significant population of cross-linked fibrinogen molecules.  In fact, a 
distinct shoulder is seen in the ion-exchange profile of Siebenlist et al.’s γ/γ′ fibrinogen 
dialyzed with factor XIII suggesting two populations of molecules may be present.  Cross-
linking of either or both γ/γ or γ/γ′ fibrinogen would complicate analysis of factor XIII 
zymogen binding since the enzyme could be actively cross-linking its substrate during the 
experiment and thus lead to false interpretations of binding data.  Another problem with these 
authors’ experimental set-up is that they performed an ammonium sulfate precipitation on 
γ/γ′ fibrinogen to remove factor XIII, but did not perform this same step on the γ/γ fibrinogen, 
perhaps somehow altering the γ/γ′ fibrinogen compared to the γ/γ fibrinogen.  Perhaps one of 
these experimental oversights led to the erroneous conclusion that factor XIII zymogen binds 
to the γ′ chain of fibrinogen. 
 The investigation described in this chapter also showed that the γ′ chain does not 
provide a binding site for the A subunits of factor XIII, either in their unactivated form 
(rFXIII) or their activated form (rFXIIIai).  As with factor XIII zymogen, ELISA binding 
curves and resultant Kds were identical for unactivated recombinant factor XIII binding to 
γ/γ, γ′/γ′, or γ/γ′ fibrinogen.  Activating recombinant factor XIII did not cause it to bind γ′ 
preferentially either; the Kds for rFXIIIai binding to γ/γ, γ′/γ′, and γ/γ′ fibrinogen, as 
determined by ELISA, were identical.  Figure 4.7 shows that rFXIIIai binding to each of 
these variants was inhibited by a similar amount of plasma fibrinogen, suggesting that the 
rFXIIIai plus variant fibrinogen interaction is the same strength for each γ or γ′ variant. 
 Although never hypothesized as such, these experiments demonstrated that the αC 
domains of fibrinogen are not binding sites for factor XIII zymogen.  ELISA experiments 
showed that the binding curve for factor XIII zymogen binding to Aα251 fibrinogen, 
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truncated at Aα residue 251, were identical to that of γ/γ fibrinogen, the normal fibrinogen 
molecule with intact Aα chains.  Inhibition experiments with plasma fibrinogen in solution 
showed that the same amount of plasma fibrinogen was required to inhibit factor XIII 
binding to Aα251 fibrinogen as was needed for normal fibrinogen. 
 Also, αC domains may not be required for optimal binding of the A subunits of factor 
XIII to fibrinogen.  ELISA binding experiments with recombinant factor XIII showed that 
binding to Aα251 fibrinogen took place with the same affinity as binding to fibrinogen that 
contained the αC domains.  A similar result was obtained for activated, active-site inhibited 
recombinant factor XIII binding to Aα251 fibrinogen or fibrin.  The αC domains have been 
suggested by Procyk et al. as a binding site for the A subunits of factor XIII, but this site was 
only investigated for the active form of the molecule (rFXIIIa), not unactivated recombinant 
factor XIII [11].  Not blocking the active site of rFXIIIa would lead to significant cross-
linking of the fibrin clot through which rFXIIIa was percolated, retarding its flow.  Addition 
of a fibrinogen fragment or antibody to the αC domain would inhibit this cross-linking, thus 
increasing the rate at which rFXIIIa passed through the clot.  Such an increase might appear 
as loss of a binding site. 
 My determination of Kd for plasma fibrin binding to factor XIII zymogen was 0.023 
+/- 0.008 µM, which is in good agreement with Naski et al.’s 1991 determination of 0.065 
+/- 0.015 µM [8].  For each fibrin(ogen) in my ELISA experiments, binding of factor XIII 
zymogen to fibrin produced a lower Kd than binding to fibrinogen (regardless of γ′ content).  
Given Janus et al.’s assertion that des-A fibrin is the true activator of factor XIII to active 
factor XIIIa [4], the increased affinity of factor XIII zymogen for fibrin versus fibrinogen 
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makes sense.  Once fibrinogen is converted to fibrin at the site of a wound, it recruits factor 
XIII to the site of activation. 
 Similarly, rFXIIIai bound more strongly to fibrin than to fibrinogen for all variants. 
This increase in affinity of rFXIIIai for fibrin compared to fibrinogen is a new observation.  
In vivo, it would be impossible to generate active factor XIII in the presence of fibrinogen 
since thrombin-catalyzed FpA cleavage takes place before thrombin-catalyzed activation 
peptide cleavage [4]. 
 Comparison of ELISA binding studies of factor XIII zymogen (A2B2), unactivated 
recombinant factor XIII (A2), and activated, active-site inhibited recombinant factor XIII 
(A2a) provides me with a framework for discussing the role of the A and B subunits of factor 
XIII in binding to fibrinogen.  Because we have learned that the γ′ chains do not play a role 
in binding to any form of factor XIII, I will focus this discussion on factor XIII binding to 
normal, recombinant γ/γ fibrinogen.  As shown in Table 4.1, the Kd for factor XIII zymogen 
binding to γ/γ fibrinogen was 0.041 +/- 0.013 µM; the Kd for rFXIII binding to γ/γ fibrinogen 
was 1.2 +/- 0.4 µM (p < 0.05 compared to FXIII); and the Kd for rFXIIIai binding to γ/γ 
fibrinogen was 0.030 +/- 0.009 µM (p = 0.05 compared to γ/γ fibrinogen).  Thus, loss of the 
B subunits from unactivated factor XIII dramatically lowered its affinity for fibrinogen, but 
activation of this protein returned its affinity to a similar, and possibly even stronger, value.  
Binding was not, however, fully abrogated by loss of the B subunits; rFXIII still bound to 
fibrinogen with a Kd of around 1 µM.  This suggests that the B subunits of factor XIII 
zymogen provide a high affinity site for binding to fibrinogen.  When they are lost, there is 
still a weak site on the A subunits that is responsible for some binding affinity and becomes a 
stronger site once factor XIII is activated. 
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This model of a high affinity binding site on the B subunits that does not negate a low 
affinity binding site present on unactivated A subunits helps to explain how platelet factor 
XIII with only A subunits could compete away plasma factor XIII from fibrinogen in 
Greenberg and Shuman’s initial study of factor XIII binding to fibrinogen.  It does not, 
however, explain their similar Kd determinations of around 0.01 µM for both forms of factor 
XIII [1].  This model is also consistent with Hornyak and Shafer’s claims that the binding 
sites on factor XIII zymogen and active factor XIIIa are separate.  They found that factor 
XIII zymogen did not inhibit binding of factor XIIIa to fibrin and thus suggested separate 
binding sites on factor XIII for when it is in its zymogen form or its active state [10].   
I have also shown that active factor XIIIa bound more strongly to fibrin than did 
factor XIII zymogen.  This makes sense physiologically for localization of active enzyme to 
an appropriate substrate.  We can conclude that the A subunit binding site has a higher 
affinity for fibrin than does the B subunit binding site, while, as discussed above, the reverse 
is true for binding to fibrinogen. 
 In summary, I have strong evidence to suggest that the γ′ chain of fibrinogen does not 
play a role in binding to any form of factor XIII.  Similarly, the αC domains of fibrinogen are 
not required for optimal factor XIII binding.  Factor XIII is able to bind to fibrinogen through 
both its A and B subunits, though it must be activated before A subunit binding takes place 
with high affinity. 
 Generally, sites of functional importance, such as binding sites, are conserved among 
species.  The γ′ chain, on the other hand, differs in human fibrinogen compared to other 
species.  The human γ′ sequence (VRPEHPAETEYDSLYPEDDL) contains six negatively-
charged amino acids and two sulfated tyrosines [19].  Rat fibrinogen has a γ′ sequence 
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(VSVEHEVDVEYP) that is much shorter than that of human γ′ with only four negatively-
charged amino acids and one tyrosine available for sulfation [20]. Bovine fibrinogen has a γ′ 
sequence similar to that of rats [21].  Such an abbreviated γ′ sequence removes a significant 
fraction of the negative charge that was suggested as a part of the factor XIII binding site.   
In addition, the amount of alternatively spliced γ′ chains differ among species.  
Human γ′ chains constitute around 10% of fibrinogen γ chains [22].  In rats, the γ′ chain is 
found in 30% of γ chains [23].  Chicken fibrinogen contains up to 50% γ′ chains, possibly 
one on every fibrinogen molecule [24].  Such variability in the frequency of the γ′ chain also 
suggests against it being a binding site for factor XIII since some species would have a 
plethora of these binding sites while others would have very few.  Future experiments must 
be performed to identify the true factor XIII zymogen binding site on fibrinogen. 
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THE γ′ CHAIN OF FIBRINOGEN AS SUBSTRATE FOR FACTOR XIII 
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Summary 
 We investigated the role of the γ′ chain as a substrate for factor XIII-catalyzed cross-
linking into γ′-γ′ or γ-γ′ dimers.  By comparing polymerization of fibrinogen in the absence 
and presence of factor XIII zymogen, we learned that addition of factor XIII to recombinant 
γ/γ fibrinogen had no effect on the basic polymerization parameters: lag time, maximal rate, 
and final absorbance.  This was also the case for both γ′/γ′ fibrinogen and a mixture of γ/γ 
with γ/γ′ fibrinogen, suggesting that the γ′ chain does not influence polymerization in the 
presence of factor XIII.  We also monitored factor XIII-catalyzed cross-linking of γ′ fibrin 
variants and found that the γ′ chain slows the initial rate of γ(′)-γ(′) dimer formation. 
 
Introduction 
 In the last chapter of this document, I demonstrated that the γ′ chain is not a binding 
site for factor XIII zymogen.  While provision of this binding site is how fibrinogen acts as a 
cofactor for factor XIII activation, I have not yet explored the effect of the γ′ chain on 
fibrinogen’s role as substrate for factor XIII.  In this chapter, I will investigate how the 
presence of the γ′ chain influences cross-linking of fibrinogen by factor XIII. 
Polymerization of Fibrinogen in the Presence of Factor XIII 
 Polymerization of fibrinogen in the presence of factor XIII was first studied by Carr, 
Gabriel, and McDonagh in 1987 [1].  They monitored polymerization for just ten minutes 
and then analyzed mass-to-length ratios after 24 hours of reaction.  The authors claim the 
following: 1) the addition of factor XIII into a polymerization reaction does not cause a 
change in lag time for the reaction, 2) the rate of turbidity increase is unchanged by addition 
of factor XIII, 3) mass-to-length ratios of fibers did not change upon addition of factor XIII, 
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and 4) fiber density increased with factor XIII present during polymerization [1].  It is 
difficult, however, to interpret these results because the authors included 5 mM CaCl2 in any 
reaction mixture without factor XIII and 10 mM CaCl2 when factor XIII was present.  
Because calcium has such a clear effect on polymerization [2], it may mask the effect of 
factor XIII in these reaction mixtures. 
 Ryan et al. performed electron microscopy studies of plasma-derived fibrin clots 
polymerized in the presence of endogenous factor XIII as well as with 1 mM factor XIII 
inhibitor to prevent cross-linking [3].  Visual inspection of the clots revealed no clear 
differences between fibrin clots formed in the presence of active factor XIII and those formed 
in its absence.  Rigorous mathematical analysis showed a small increase in fiber length and 
concomitant decrease in fiber diameter when factor XIII was present.  There was no change 
in fiber or branch-point density [3].  Lim and coworkers presented an abstract of similar 
findings from scanning electron microscopy of fibrin clots formed in the presence of factor 
XIII [4].  They also demonstrated a slower rate of lateral aggregation and lower final 
absorbance when monitoring polymerization in a spectrophotometer.  Because they observed 
these same results upon polymerization of recombinant Aα251 fibrinogen with factor XIII, 
they hypothesized that factor XIII’s effect on fibrin clot structure occurs through cross-
linking of γ chains [4].  My recombinant γ′ chain variants provide a way to further these 
studies. 
Factor XIIIa-Catalyzed Cross-Linking of Fibrin 
 In 1995, Taubenfeld and coworkers demonstrated that the C-terminus of the γ chain is 
necessary for factor XIIIa-catalyzed cross-linking of fibrin [5].  They showed that addition of 
increasing concentrations of 4A5, a monoclonal antibody to C-terminal γ chain residues 402-
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411, could inhibit cross-linking.  The authors suggested two modes of action for this 
inhibition.  One suggestion was that the antibody sterically blocks factor XIII, preventing it 
from gaining access to the γ-chain cross-linking sites.  Another method of action was that it 
may prevent fibrin from assembling into the proper orientation for cross-linking to take place 
[5].  In either case, these observations point out that changes to the C-terminus of the γ chain, 
such as removal of the four C-terminal amino acids and addition of a large, mobile, and 
highly-charged region such as the γ′ chain, may influence the ability of factor XIII to cross-
link its fibrin substrate. 
 How the γ′ chain affects the rate and extent of factor XIII-catalyzed cross-linking of 
fibrin has been a subject of debate [6],[7],[8].  Moaddel, Falls, and Farrell published a study 
in 2000 investigating the role of plasma-derived γ/γ′ fibrinogen in factor XIII activation [6].  
They incubated a fixed amount of factor XIII (43 nM) with increasing concentrations of 
fibrinogen in the presence of 1 mM CaCl2 and 1 unit/mL thrombin for 6 minutes, then 
quenched the reaction and ran it on a reducing gel.  They determined the concentration of γ-
γ(′) dimers in each sample by dividing the optical density of the γ-γ(′) band by that of the β 
chain band.  Results of this experiment showed that more cross-links form in γ/γ′ fibrinogen 
compared to γ/γ fibrinogen.  A similar experiment quantifying α-chain multimer formation 
demonstrated a large excess of α-multimers in γ/γ′ fibrinogen compared to γ/γ fibrinogen.  
They also showed that γ/γ′ fibrinogen is a more effective cofactor for factor XIII activation 
by incubating factor XIII with thrombin and γ/γ or γ/γ′ fibrinogen and then measuring 5-
(biotinamido)pentylamine incorporation into N,N′-dimethlycasein [6]. 
 Siebenlist et al.’s results are virtually opposite those of Moaddel et al.  Instead of 
measuring cross-linking versus concentration of fibrinogen, Siebenlist and coworkers looked 
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at cross-linking of plasma γ/γ versus γ/γ′ fibrinogen over time [7].  They showed that at early 
timepoints, γ/γ′ fibrinogen cross-linking is delayed with respect to γ/γ fibrinogen, but they 
quickly achieve the same rate of cross-linking and plateau of percent cross-linked chains.  
These experiments were performed with 0.124 µM factor XIII, 5 mM CaCl2, and 0.5 U/mL 
thrombin.  They also performed experiments to measure thrombin cleavage of activation 
peptide from factor XIII in the presence of fibrinogen and found that γ/γ fibrinogen is a better 
cofactor for this reaction than is γ/γ′ fibrinogen [7].   
 The two investigations into factor XIII-catalyzed cross-linking of γ/γ′ fibrinogen 
compared to γ/γ fibrinogen were performed differently at different conditions; not 
surprisingly their conclusions also differ.  In addition to these differences, Siebenlist also 
pointed out that Moaddel’s plasma fibrinogen samples were not free of co-purifying factor 
XIII which would certainly affect cross-linking rates [7].  In a letter to the editor, Farrell 
provides data suggesting that his fibrinogen samples are not contaminated with factor XIII 
and claims that Siebenlist’s method of measuring factor XIII activation by activation peptide 
release is flawed.  Siebenlist refutes both of these assertions in a rebuttal [8].  Once again, my 
recombinant fibrinogen γ′ variants provide a way to consider the role of the γ′ chain as 
substrate for factor XIII, without having to worry about purification from plasma, removal of 
factor XIII, or any other complications of plasma-derived proteins. 
 
Materials and Methods 
Materials 
Human plasma fibrinogen depleted of plasminogen, fibronectin, and factor XIII (lots 
030411 and 050518) was purchased from American Diagnostica (Stamford, CT).  Human 
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factor XIII (lots 850A and 3040P) and human α-thrombin (lot 2690PR) were purchased from 
Enzyme Research Laboratories (South Bend, IN).  Recombinant γ′/γ′ and γ/γ′ fibrinogen were 
expressed and purified as described in Chapter Two.  Normal, recombinant γ/γ fibrinogen 
was prepared as described [9] and purified as described [10].  Both fibrinogen (plasma and 
recombinant) and factor XIII (plasma and recombinant) were dialyzed extensively against 20 
mM HEPES pH 7.4, 150 mM NaCl (HBS). 
Polymerization of Fibrinogen in the Presence of Factor XIII 
 Polymerization reactions were performed in 100 µL in Corning half-area untreated 
polystyrene microtiter plates under the following conditions: 
0.15 mg/mL fibrinogen (plasma, recombinant γ/γ, recombinant γ′/γ′, or a mixture of 
90% recombinant γ/γ + 10% recombinant γ/γ′) 
 20 mM HEPES pH 7.4 
 5.0 mM CaCl2 
 NaCl to bring ionic strength to 0.15 
 1.0 nM (0.10 U/mL) α-thrombin 
 with or without 15 µg/mL factor XIII zymogen 
Reactions were prepared without factor XIII or thrombin and incubated at 4°C for 30 minutes 
followed by 30 minutes at room temperature.  Factor XIII was added to the appropriate wells 
followed by 10 µL of 10 nM α-thrombin in HBS to initiate clot formation.  Turbidity was 
monitored on a SpectraMax 340PC microtiter plate reader from Molecular Devices at 350 
nm every 10 seconds for 90 minutes.  Data was recorded in SoftmaxPro version 4.3.1.  
Absorbance was plotted versus time for each polymerization curve.  Lag time and final 
absorbance of the clot were determined by inspection, while Vmax (maximal rate of change) 
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was determined from the five points on the curve with the highest slope as determined by 
Softmax. 
Factor XIII-Catalyzed Cross-Linking of Fibrinogen 
 Cross-linking reactions were performed in HBS + 5.0 mM CaCl2 + 0.50 mM DTT.  
Recombinant γ/γ, γ′/γ′, or γ/γ′ fibrinogen (0.30 mg/mL) was mixed with factor XIII zymogen 
(0.50 µg/mL).  We added 0.20 U/mL thrombin to start the reaction, quickly mixed the sample 
by pipetting, and transferred 10 µL to each of 7 tubes, all in the first 60 seconds after 
thrombin addition before the solution became viscous.  The reaction was quenched at 
designated timepoints (0, 1, 2, 5, 10, 30, and 60 minutes) by addition of 10 µL of 2X 
Laemmli buffer (30mM Tris, pH 8.5, 4% SDS, 0.02% bromophenol blue, 4% glycerol) and 
12% BME.  The Laemmli/BME solution was placed in the 0 timepoint tube prior to the start 
of the reaction for immediate quenching.  Complete solubilization was achieved by 
incubation of the quenched reactions at 37°C overnight prior to boiling.  Samples were run 
on an 11% gel with an extra tall stacking gel at 60 – 80V to increase separation of γ and γ′ 
chains, then stained with Coomassie R-250.  The formation of γ-γ dimers was quantitated by 
densitometry using ImageJ (NIH, Bethesda, MD).  The intensity of the γ-γ dimer band was 
divided by the total intensity of γ monomers + γ-γ dimers to calculate the ratio of dimers 
formed.  The γ′-γ′ dimer band was measured for γ′/γ′ fibrinogen, while the sum of γ-γ, γ-γ′, 
and γ′-γ′ bands was determined for γ/γ′ fibrinogen. 
 We also compared cross-linking of each fibrinogen variant using active factor XIIIa.  
Factor XIII (1.67 µg/mL) in HBS + 5 mM CaCl2 + 0.5 mM DTT was incubated for 30 
minutes at 37°C with 0.67 U/mL thrombin.  This activation was set up so that when the 
thrombin / factor XIIIa mixture was added to fibrinogen, the concentration of factor XIII 
 134 
would be 0.50 µg/mL and the concentration of thrombin would be 0.20 U/mL.  Reactions 
were quenched and run on 11% gels as described above. 
 
Results 
Polymerization of Fibrinogen in the Presence of Factor XIII 
 To determine whether the addition of factor XIII has a different effect on 
polymerization of fibrinogens with γ′ chains than it does on those without, I performed 
polymerization experiments, much as described in Chapter Three of this document, in the 
presence and absence of 15 µg/mL factor XIII zymogen.  The fibrinogens I studied were 
plasma fibrinogen with ~90% γ/γ molecules and ~10% γ/γ′ molecules, recombinant γ/γ, 
recombinant γ′/γ′, and a mixture of 90% recombinant γ/γ + 10% recombinant γ/γ′.  This 
recombinant mixture was designed to mimic the γ′ content of plasma fibrinogen to determine 
whether differences between plasma and recombinant fibrinogen were due to the presence of 
γ′ chains. 
 I mixed 0.15 mg/mL fibrinogen with 5.0 mM CaCl2, 20 mM HEPES, and NaCl to 
bring ionic strength to 0.15.  I incubated this mixture at 4°C for 30 minutes and then at room 
temperature for 30 minutes to make sure all components were at equilibrium.  Just before 
addition of thrombin, I added 15 µg/mL factor XIII to selected wells, and then started 
polymerization by addition of 0.10 U/mL thrombin.  Results of these polymerizations are 
shown in Figure 5.1; lag time, Vmax, and final absorbance are listed in Table 5.1. 
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Figure 5.1.  Polymerization curves for 0.15 mg/mL plasma fibrinogen, recombinant γ/γ, 
recombinant γ′/γ′, and 90% recombinant γ/γ + 10% recombinant γ/γ′ fibrinogen in the 
absence (red) and presence (blue) of 15 µg/mL factor XIII zymogen.  Absorbance was read 
at 350 nm every 10 seconds for 5400 seconds.  Insets contain detail of the first 500 seconds 
of polymerization reaction. 
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Polymerization Parameters With and Without Factor XIII 
  
Plasma 
Fgn     
Condition Lag Time Vmax Final OD 
  (sec) (munits/min)   
Fibrinogen Only       
Mean 43 47.3 0.14 
Standard Deviation 5 10.4 0.02 
Fibrinogen + FXIII       
Mean 42 34.2 0.11 
Standard Deviation 4 9.9 0.02 
P Values 0.27 < 0.05 < 0.05 
        
  γ/γ Fgn     
  Lag Time Vmax Final OD 
  (sec) (munits/min)   
Fibrinogen Only       
Mean 53 43.9 0.13 
Standard Deviation 14 5.3 0.02 
Fibrinogen + FXIII       
Mean 47 44.3 0.13 
Standard Deviation 10 7.9 0.03 
P Values 0.18 0.46 0.33 
        
  γ'/γ ' Fgn     
  Lag Time Vmax Final OD 
  (sec) (munits/min)   
Fibrinogen Only       
Mean 27 32.1 0.11 
Standard Deviation 6 4.9 0.02 
Fibrinogen + FXIII       
Mean 23 31.8 0.11 
Standard Deviation 12 10.2 0.01 
P Values 0.34 0.48 0.38 
        
  
γ/γ  + γ/γ' 
Fgn     
  Lag Time Vmax Final OD 
  (sec) (munits/min)   
Fibrinogen Only       
Mean 73 36.9 0.11 
Standard Deviation 16 5.7 0.03 
Fibrinogen + FXIII       
Mean 60 39.2 0.12 
Standard Deviation 15 8.8 0.02 
P Values 0.09 0.30 0.34 
 
Table 5.1.  Lag time, Vmax, and final absorbance are reported for each fibrinogen variant or 
mixture with and without factor XIII.  P values < 0.05 are highlighted in red, indicating a > 
95% chance that the difference between polymerization with and without factor XIII is 
significant. 
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 Polymerization of plasma fibrinogen in the presence of factor XIII led to a similar lag 
time, but both a decreased maximal velocity and lower final absorbance compared to 
polymerization without factor XIII, suggesting the presence of thinner fibers.  As shown in 
Table 5.1, these differences were significant.  Neither recombinant γ/γ nor γ′/γ′ fibrinogen 
displayed these changes upon addition of factor XIII.  To approximate the γ′ content of 
plasma fibrinogen, 90% recombinant γ/γ fibrinogen was mixed with 10% recombinant γ/γ′ 
fibrinogen heterodimer.  Like the other recombinant fibrinogens, this mixture did not display 
a change in polymerization parameters upon addition of factor XIII zymogen.  These results 
suggest that something inherent in plasma fibrinogen, other than the presence of γ′ chains, is 
responsible for the thinner fibers that form in the presence of factor XIII. 
Factor XIIIa-Catalyzed Cross-Linking of Fibrin Variants 
 We studied the rate of cross-linking of γ/γ, γ′/γ′, and γ/γ′ fibrinogen in the presence of 
0.20 U/mL thrombin and 0.50 µg/mL factor XIII zymogen.  To determine the percent γ(′)-γ(′) 
dimer formed, we divided the intensity of γ-γ dimer bands by the total intensity of γ monomer 
+ γ-γ dimer bands present in each sample.  This ratio was plotted versus time to determine the 
rate of cross-linking.  A representative cross-linking gel is shown for each of the three 
fibrinogen variants in Figure 5.2.  
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Figure 5.2.  Representative 11% reducing gels of cross-linking reactions for γ/γ, γ′/γ′, and γ/γ′ 
fibrinogen.  Recombinant fibrinogen (0.30 mg/mL) and factor XIII zymogen (0.50 µg/mL) 
were mixed with thrombin (0.20 U/mL) and incubated for the time periods shown above each 
gel.  Samples were quenched with Laemmli buffer and BME, incubated at 37°C overnight, 
boiled, run on an 11% gel, and stained with Coomassie. 
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 Figure 5.3 shows a representative cross-linking profile for factor XIII-catalyzed 
cross-linking of γ/γ, γ′/γ′, and γ/γ′ fibrinogen.  A smooth curve was fit to the data for ease of 
comparison.  γ/γ Fibrinogen appeared to have a faster initial rate of cross-linking than the γ′ 
variants, but γ′/γ′ fibrinogen had approximately the same extent of γ-γ dimer formation by 60 
minutes, while γ/γ′ never moved past approximately 20% dimers.  
It was possible to obtain a quantitative comparison of cross-linking rates by looking 
at the initial rate of cross-linking, before γ-γ dimerization slows and the dimer % in each 
sample becomes constant.  We determined the cross-linking rate, in % dimers / minute, 
between 0 and 10 minutes of reaction time.  Figure 5.4 shows this average rate for each 
fibrinogen upon factor XIII-catalyzed cross-linking. 
The initial rates, standard deviations, and Student’s t-test p values for factor XIII-
catalyzed cross-linking are listed in Table 5.2.  These initial rates were slower for variants 
with a γ′ chain compared to γ/γ fibrinogen. 
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Figure 5.3.  Representative cross-linking curves for γ/γ, γ′/γ′, and γ/γ′ fibrinogen (0.30 
mg/mL) catalyzed by 0.50 µg/mL factor XIII and 0.20 U/mL thrombin.  % γ-γ dimers are 
determined by dividing the intensity of the γ-γ dimer band (γ′-γ′ for γ′/γ′ fgn or γ-γ + γ′-γ′ + γ-
γ′ for γ/γ′ fgn) by the sum of the γ monomer band + the γ-γ dimer band. 
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Figure 5.4.  Initial rate of factor XIII-catalyzed cross-linking for the average of 3-4 reactions 
of γ/γ, γ′/γ′, or γ/γ′ fibrinogen.  Data points between 0 and 10 minutes were fit to a line, the 
slope of which (% γ-γ dimers / minute) describes cross-linking rate. 
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γ(′)-γ(′) Dimer Formation By Factor XIII 
  Fibrinogen     
  γ/γ Fgn γ'/γ' Fgn γ/γ' Fgn 
Rate (% dimers/min) 0.053 0.036 0.020 
Standard Deviation 0.005 0.016 0.01 
        
P (compared to γ/γ)   0.08 < 0.05 
Table 5.2.  Initial rate (% γ-γ dimers/min) and standard deviation determined for each 
fibrinogen variant cross-linked by factor XIII zymogen.  P values were determined by 
Student’s t-test to compare variant fibrinogens. 
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Discussion 
 Close observation of Figure 5.1 indicates a small difference in the shape of the 
polymerization curve measured in the presence of factor XIII compared to those without.  
This was the case for each fibrinogen studied, both with or without γ′ chains.  The 
absorbance at later timepoints did not quite level off the way it did without factor XIII.  This 
slow, continued fiber growth was also observed by Carr et al [1], and suggests continued 
fiber cross-linking and rearrangement even an hour after addition of thrombin. In all other 
respects, however, recombinant fibrinogens in the presence of factor XIII polymerized in 
much the same manner as they did in the absence of factor XIII.  This finding is consistent 
with the observations made by Ryan and coworkers of only very subtle differences in clot 
architecture in the presence or absence of active factor XIII [3]. 
 There was a striking contrast between the muted response of recombinant fibrinogen 
to factor XIII and the dramatic change in polymerization of plasma fibrinogen when factor 
XIII is added.  While lag time remained unchanged, addition of factor XIII to plasma resulted 
in a significant decrease in both Vmax (reflecting rate of lateral aggregation) and final OD 
(reflecting fiber thickness).  These two observations are much more similar to Lim’s 
assertions than Ryan’s publication [4],[3].  Clearly, there was some element of the plasma 
fibrinogen that caused addition of factor XIII to have such a striking effect compared to 
recombinant fibrinogen.  This element may be the presence of a contaminating protein or a 
polymorphism that is not present in recombinant fibrinogen.  Further experiments would be 
needed to determine the origin of these differences. 
 Factor XIII zymogen-catalyzed cross-linking began with an initial rate that was faster 
for γ/γ fibrinogen than for γ′/γ′ or γ/γ′ fibrinogen.  After this initial burst, however, the cross-
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linking of γ′/γ′ fibrinogen increased in speed so that by 60 minutes of incubation, it had 
formed approximately the same amount of γ′-γ′ dimers as γ/γ fibrinogen had formed γ-γ 
dimers.  γ/γ′ Fibrinogen, on the other hand, continued to be cross-linked at a slow speed and 
plateaued at a lower dimer percentage.  These results suggest that either 1) the presence of 
the γ′ chain diminishes fibrinogen’s role as cofactor for factor XIII activation, or 2) the 
presence of γ′ chains inhibits γ(′)-γ(′) dimer formation at early timepoints.  For some reason, 
this inhibitory activity is no longer present at later timepoints for γ′/γ′ fibrinogen, but remains 
in place for γ/γ′ fibrinogen.   
 We attempted to distinguish between these two options by using active factor XIIIa in 
our cross-linking experiments.  We activated 1.67 µg/mL factor XIII with 0.67 U/mL 
thrombin so that upon addition to fibrinogen, the concentration of factor XIII would be 0.50 
µg/mL and the concentration of thrombin would be 0.20 U/mL, just as for the factor XIII 
zymogen experiments.  We did not include fibrinogen as a cofactor in this mixture because it 
is the variable in question.  Upon addition of this AP-cleaved factor XIII to fibrinogen, the 
initial rate of dimer formation for each fibrinogen variant was less than half the rate for factor 
XIII zymogen-catalyzed cross-linking, not greater as we expected for pre-activated factor 
XIIIa (data not shown).  This finding indicated that without including fibrinogen as a 
cofactor during factor XIII activation, AP-cleaved factor XIII is not in an active form, and 
therefore will not help us determine whether the γ′ chain has an effect on factor XIII 
activation. 
 Although we cannot fully explain the reason why the γ′ chain slows factor XIII-
catalyzed dimer formation, our results are quite similar to those of Siebenlist and coworkers 
[7].  They also found a delayed initial rate of γ(′)-γ(′) dimer formation for γ/γ′ fibrinogen 
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compared to γ/γ fibrinogen, although their results do not appear to be as statistically 
significant as are ours.  Because we did not perform our experiments at variable 
concentrations of fibrinogen, we cannot directly compare our results with those of Moaddel 
et al [6].  However, they claim a small enhancement in γ-γ′ dimer formation compared to γ-γ 
formation, and we do not reach such a conclusion. 
 In summary, we find addition of factor XIII during polymerization has little effect on 
the basic polymerization parameters, and the presence of the γ′ chain does not change this 
finding.  Cross-linking of the γ′ chain by factor XIII, however, is slower upon the start of the 
reaction, but may rebound to the rate of γ/γ fibrinogen by later timepoints. 
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CONCLUSION 
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 Expression of γ′/γ′ and γ/γ′ fibrinogen in CHO cells was a significant portion of the 
work described in this document.  From characterization of this expression system, I learned 
that secretion of γ′ chains occurs with the same efficiency as secretion of γ chains.  The 
amount of γ′ protein produced is simply determined by the amount of message for this chain 
introduced into the cells; there is no impediment to translation of the mRNA message into γ′ 
protein or secretion of this protein from the cell.  In addition, it appears that each γ or γ′ chain 
has an equal chance of assembling into a heterodimer or a homodimer, and the ratio of these 
products is determined by the ratio of γ to γ′ chains present inside the cell. 
 The next step in this kind of study would be to translate what we have learned about 
γ′ expression in CHO cells into humans.  To my knowledge, no one has ever compared γ′ 
fibrinogen message levels from human hepatocyte cells with γ′ protein levels in blood 
samples from the same donor.  Such an experiment would demonstrate whether, as we have 
shown in CHO cells, expression of γ′ protein in human plasma occurs with the same 
efficiency as expression of the γ chain.  If there is no difference in the level of γ′ protein 
compared to γ′ mRNA, then we can conclude that the actual determinant of γ′ fibrinogen 
levels in human plasma is the frequency of alternative splicing into this sequence.  Lovely 
and coworkers demonstrated the existence of elevated concentrations of γ/γ′ fibrinogen in 
coronary artery disease patients [1].  Inclusion of such patients could provide even more 
information for the study described. 
 Next I characterized the polymerization of γ′/γ′ and γ/γ′ fibrinogen compared to 
normal γ/γ fibrinogen.  At 10 µM calcium, the lag time of polymerization was significantly 
diminished for γ′/γ′ fibrinogen compared to γ/γ or γ/γ′ fibrinogen.  As the concentration of 
calcium increased, however, this parameter returned to a normal value.  Perhaps the high 
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concentration of extended γ′ chains in the γ′/γ′ homodimer causes some steric or electrostatic 
repulsion that prevents proper alignment of the fibrin monomers into a protofibril.  Then 
when calcium is added to the reaction mixture, it interacts with the negatively charged γ′ 
sequence to mitigate the repulsion between molecules so that, in turn, polymerization returns 
to a normal rate. 
 Polymerization experiments also demonstrated that the presence of the γ′ chain, 
whether in heterodimer or homodimer form, led to a diminished rate of polymerization and a 
decrease in the final absorbance of the clot.  Both of these observations may be explained by 
an increase in the rate constant for fiber initiation, or a decrease in the rate of lateral 
aggregation.  Because this effect was seen at each concentration of calcium studied, I do not 
believe that the decrease is due to electrostatic repulsions since the addition of higher 
concentrations of calcium should counterbalance the negative charge of the γ′ chain.  The γ′ 
region, however, is highly flexible, and may inhibit the formation of fibers by steric 
hindrance. 
 I studied the initial rate of factor XIIIa-catalyzed cross-linking of recombinant fibrin 
because at this point the γ(′)-γ(′) dimer formation rate is linear, and it best reflects the early 
steps necessary to make γ or γ′ fibrinogen a substrate for factor XIIIa.  I found that the initial 
rate of γ/γ cross-linking is significantly faster than that of either γ′/γ′ or γ/γ′ fibrinogen.  As I 
discussed in Chapter Five, there are two possibilities for this inhibition of cross-linking by 
the γ′ chain.  One possible reason is that γ′/γ′ and γ/γ′ fibrinogen are not as efficient cofactors 
for factor XIII activation as is γ/γ fibrinogen.  Moaddel and coworkers’ experiments with γ/γ 
and γ/γ′ fibrinogen purified from plasma suggest that this is not the case.  In fact, they 
demonstrated enhanced factor XIII activation in the presence of γ/γ′ fibrinogen [2].  This 
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finding suggests that a slower activation of factor XIII in the presence of γ′/γ′ or γ/γ′ 
fibrinogen does not occur. 
 The more likely possibility for a slower rate of cross-linking for γ′ fibrinogen is that 
the presence of the γ′ chain presents some structural inhibition to dimerization.  Just as we 
observed for polymerization of γ′ fibrinogen, in cross-linking reactions the γ′ chain may 
block access to the cross-linking sites in the D region at Gln 398 and 399 or Lys 402.  No 
crystal structure yet exists for the γ′ chain or the γ chain cross-linking sites because both are 
such flexible regions [3].  This flexibility suggests motion that may be impacted by the 
presence of the γ′ chain. 
 Mass spectrometry experiments have confirmed that tyrosine 422 of the γ′ chain in 
my recombinant γ′/γ′ fibrinogen is sulfated.  We have no evidence that would suggest 
tyrosine 418 is also sulfated, although we also have no evidence that it is not.  The fact that 
Tyr 422 is sulfated means that the extra negative charge of the sulfate group is present on our 
γ′ chain, just as it is in plasma fibrinogen.  Sabo and coworkers have shown that in the 
binding of γ′ to thrombin, only one tyrosine must be sulfated and it is tyrosine 422 that is 
more important for this interaction than tyrosine 418 [4].  Taken together, these two findings 
suggest that if the γ′ chain of plasma fibrinogen really were a binding site for factor XIII, so 
should be our recombinant γ′ chain.  However, we found no evidence of enhanced binding of 
factor XIII zymogen to the γ′ chain of fibrinogen.  This means that unlike previous assertions 
[5], the γ′ chain is not a binding site for factor XIII zymogen. 
 From the experiments described in this document, I am unable to postulate a more 
likely binding site.  Addition of the γ′ chain does not increase factor XIII binding compared 
to normal fibrinogen; removal of the αC domains does not decrease factor XIII binding 
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compared to normal fibrinogen.  Thus, it seems that the binding site is somewhere other than 
these two regions.  
 My binding experiments, do, however provide information for the presentation of a 
unified model of factor XIII A and B subunit binding to fibrinogen and fibrin.  In the 
interaction of factor XIII zymogen and fibrinogen, the B subunits provide a higher affinity 
binding site than do the A subunits.  Activation of factor XIII strengthens the binding of the 
A subunits to fibrinogen.  This effect may be due to a conformational change in the A 
subunits that better allows fibrinogen to interact with factor XIIIa’s binding site or to the 
removal of B subunits which block a high affinity site.   
 Both factor XIII zymogen and active factor XIIIa bind more strongly to fibrin than to 
fibrinogen.  Since fibrin is the substrate of factor XIIIa, this increased affinity may help 
localize factor XIII(a) to molecules that are ready to be cross-linked.  Loss of the αC 
domains from fibrin renders factor XIII zymogen binding to Aα251 fibrin weaker than the 
zymogen’s binding to other fibrin variants.  This finding suggests that it is the mobilization 
of the αC domains that creates the higher affinity binding of factor XIII zymogen to fibrin.   
 The next step in these experiments would be to determine where the binding site on 
fibrinogen is for factor XIII zymogen, since it is not the γ′ chain.  Clearly, there is some 
interaction between these two proteins since factor XIII co-purifies with fibrinogen [6].  My 
ELISA binding system could be used to screen fibrinogen fragments from different parts of 
the molecule.  Those that led to weaker factor XIII binding could then be further 
characterized to determine the location of this binding site. 
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THROMBIN-INDEPENDENT ACTIVATION OF FACTOR XIII 
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Summary 
 In addition to the well-known thrombin-catalyzed pathway for activation of factor 
XIII, another method of generating active factor XIIIa exists that does not require thrombin-
catalyzed activation peptide cleavage [1].  Because such a pathway will likely lead to 
activation of factor XIII zymogen during binding experiments, we performed these 
experiments to characterize this activation method.  It was shown qualitatively that thrombin-
independent activation of factor XIII takes place in the presence of calcium and fibrinogen 
after no more than an hour of incubation.  A quantitative measure of factor XIII activity, the 
dansylcadaverine incorporation experiment, demonstrated that factor XIII activity increased 
with increasing concentration of calcium and that fibrinogen was a required cofactor at low, 
physiological levels of calcium.  Native electrophoresis indicated that activation by calcium 
and fibrinogen leads to factor XIII that has a different structure from thrombin-activated 
factor XIIIa. 
 
Introduction 
 The “traditional” activation process for factor XIII conversion to factor XIIIa is 
catalyzed by thrombin and was described in the Introduction to this document.  In short, 
thrombin catalyzes cleavage of the activation peptide blocking the active site of one of the 
two A subunits in the molecule [2], [3].  Next, B subunits dissociate from the cleaved A 
subunits, and the A2 dimer changes conformation to reveal the active site [4].  In addition to 
this well-known thrombin-catalyzed pathway for activation of factor XIII, a thrombin-
independent pathway for activation has also been observed.  In 1978, Credo and coworkers 
first described this pathway.  At calcium concentrations of 50 mM or above, they observed 
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incorporation of radiolabeled iodoacetamide into the active site of the enzyme.  This activity 
was not affected by the presence of fibrinogen, a cofactor of thrombin-catalyzed activation of 
factor XIII [1].  In the presence of EDTA activation was reversed [5].  
 Thrombin-independent activity at high concentrations of calcium is neither 
physiologically relevant, nor a factor in the binding experiments described in chapter 4, but 
recently such an activation pathway was described at lower concentrations of calcium.  
Siebenlist et al. demonstrated by SDS-PAGE the formation of γ-γ dimers at concentrations of 
calcium as low as 50 µM, and the appearance of Aα polymers at slightly higher 
concentrations, in the mM range, when 3 mg/mL fibrinogen and 100 Loewy units/mL factor 
XIII were incubated for one hour without thrombin and with various concentrations of 
calcium.  This phenomenon is also seen with platelet factor XIII (A2).  It lacks the several 
minute lag time before generation of activity that plasma factor XIII displays.  γ/γ Fibrinogen 
was shown to be a better substrate for thrombin-independent activation of factor XIII than 
γ/γ′ fibrinogen by measuring the percent insoluble fibrinogen generated over time.  
Thrombin-independent activity is highly substrate-dependent.  When the nonphysiogical 
substrate cadaverine was incorporated into N,N’-dimethylcasein, factor XIII displayed 
significantly less activity than it did with fibrinogen as substrate.  The authors of this study 
concluded from these observations that fibrinogen may bind near the active site of factor 
XIII, thereby inducing a conformational change that leads to activation.  Thrombin-
independent activation is faster for platelet factor XIII which lacks B subunits to block the 
active site.  The binding is less favorable for γ/γ′ fibrinogen.  They claim that this effect is 
due to the B subunits of factor XIII binding to the γ′ chain and preventing active site binding 
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[6], but based on the results described earlier in this document, this particular interpretation 
may be erroneous. 
 Whether or not thrombin-independent activation is relevant in vivo remains in 
question.  A recent challenge to the above mentioned study suggested that if thrombin-
independent activation of factor XIII took place as described, then fibrinogen dimers and 
multimers should be found in circulation.  Since virtually none of these multimers are 
detected with a detection limit of < 0.5%, this activation is likely an in vitro phenomenon [7].  
The authors of the original study dispute the assertion that cross-linked chains are not found 
in circulation based on their previous work demonstrating the existence of intramolecularly 
cross-linked Aα and γ chains [8].  They claim that in vitro effects are not responsible for the 
activity of factor XIII zymogen and more attention should be paid to the underlying 
mechanism for this activity [9].  Debate continues as to the nature and existence of thrombin-
independent activation at physiological concentrations of calcium. 
 Consideration of this thrombin-independent activation at low concentrations of 
calcium explains the recent criticism of Moaddel’s analytical ultracentrifugation study of 
factor XIII binding to fibrinogen [10], [6].  Sedimentation equilibrium studies are run at a 
slow speed that requires long experimental runs.  Incubation of fibrinogen and factor XIII at 
1 mM CaCl2 for hours to days would certainly lead to some degree of factor XIII activation 
and formation of fibrinogen dimers.  These dimers complicate the analysis of sedimentation 
equilibrium experiments by forming covalent attachments between the fibrinogen monomers 
whose noncovalent associations are being measured. 
 The goal of this investigation is to further characterize the process that takes place 
during ultracentrifugation and other experiments that involve lengthy incubations of 
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fibrinogen and factor XIII in the presence of CaCl2.  Siebenlist’s work extensively outlined 
the ways in which thrombin-independent activation of factor XIII could be accelerated; I 
wished to determine just which cofactors were necessary for minimal activation as well as 
what form was taken by this alternatively-activated factor XIII. 
 
Materials and Methods 
Materials 
 All reagents came from Fisher or Sigma, unless otherwise noted.  Human fibrinogen 
that was plasminogen, fibronectin, and factor XIII depleted came from American Diagnostica 
(Stamford, CT) (lot 030411).  Human factor XIII (lot 850A) and human α-thrombin (lot 
2690PR) came from Enzyme Research Laboratories (South Bend, IN).  Hirudin (lot B68947) 
and HRP-conjugated polyclonal goat anti-mouse IgG were purchased from Calbiochem (San 
Diego, CA).  Rabbit monoclonal anti-fibrinogen γ chain (NC-15) custom antisera was 
purchased from Hazleton Research Products (Princeton, NJ); antibody Y-18 was from Dr. 
Willem Nieuwenhuizen at the Foundation of Liver Cell and Endothelial Cell Technology, 
Netherlands.  HRP-conjugated polyclonal goat anti-rabbit IgG was purchased from 
Oncogene.  96-well microtiter EIA/RIA medium-binding plates were purchased from 
Corning. 
Monitoring Cross-Link Formation by Coomassie Gel and Western Blot 
 Fibrinogen (3.0 mg/mL) and factor XIII (0.030 mg/mL) were incubated at room 
temperature for up to two days.  At appropriate timepoints, tubes containing the reaction 
mixture were quenched by reducing Laemmli buffer.  Samples were run on an 11% SDS gel 
stained with Coomassie or immunoblotted according to the protocol described in Chapter 2.  
 158 
To visualize γ chain bands, membranes were probed with anti-γ chain antibody NC-15 + 
HRP-conjugated anti-mouse IgG.  To probe for Aα chain bands, membranes were developed 
with anti-Aα chain antibody Y-18 + HRP-conjugated anti-mouse IgG.  
Cofactor Requirement Experiments 
 To probe the requirement for calcium as a cofactor in thrombin-independent 
activation of factor XIII, fibrinogen (8.8 µM) and factor XIII (8.8 µM) were incubated in 
HBS + 1.0 mM CaCl2 or 1.0 mM EDTA for 2 days.  One EDTA sample was spiked with 3.0 
mM CaCl2 for 5 minutes after the 2 day incubation.  All samples were reduced and run on an 
11% gel as described above.  To determine if fibrinogen was required, I performed a similar 
experiment incubating factor XIII (8.8 µM) and CaCl2 (1.0 mM) with or without fibrinogen 
(8.8 µM) for 2 days.  I added 8.8 µM fibrinogen back to the fibrinogen-free reaction mixtures 
for 5 minutes and then the samples were reduced and run on an 11% gel. 
Dansylcadaverine Incorporation 
 Factor XIII (0.30 mg/mL) was thrombin-independently activated in 10 µL overnight.  
To generate this activation, factor XIII was incubated with the appropriate concentration of 
CaCl2 (1.0 mM unless otherwise noted) with or without 0.30 mg/mL fibrinogen (plasma or 
recombinant) in TBS.  Thrombin-activated factor XIII was prepared by incubating 0.50 
mg/mL factor XIII with 2.5 U/mL thrombin in proteolytic preactivation buffer (10mM DTT 
+ 20 mM CaCl2 in TBS) for 20 minutes at 37°C.  At the end of this incubation, thrombin was 
inactivated by the addition of 5.0 U/mL hirudin.  Reactions were run in a 96-well plate.  
CaCl2 concentration was adjusted to 1.0 mM for the incorporation reaction, N,N′-
dimethylcasein was added (20 mg/mL), and volume was brought to 90 µL with incorporation 
buffer (5.0 mM DTT in TBS).  The incorporation reaction was initiated with the addition of 
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2.5 mM dansylcadaverine.  The reaction was followed by fluorescence with excitation at 355 
nm and emission at 495 nm monitored for 2 hours.  Incorporation was quantitated by 
calculating the rate of fluorescence increase over time. 
Native Gels 
 Factor XIII (3.0 µg) was mixed with fibrinogen (3.0 µg) and variable concentrations 
of CaCl2 and incubated overnight at room temperature.  Another sample of factor XIII (3.0 
µg) was mixed with 10 U/mL thrombin, 3.0 µg fibrinogen, and 1.0 mM CaCl2 and incubated 
at 37°C for 20 minutes.  Samples were mixed with native sample buffer (40% glycerol + 
0.01% bromophenol blue in 62.5 mM Tris, pH 6.8) and loaded onto a 4-15% precast Tris-
glycine gel.  The gel was run with native running buffer (25 mM Tris-HCl, pH 8.3 + 192 mM 
glycine) and stained with Coomassie. 
 
Results 
Factor XIII Zymogen Catalyzes Cross-linking of Fibrinogen at 1 mM CaCl2 
 Factor XIII (0.030 mg/mL), factor XIII-free plasma fibrinogen (3.0 mg/mL), and 
calcium (1.0 mM) were incubated at room temperature for various timepoints up to 2 days, 
then reduced and run on an 11% gel.  Starting at 1 hour, a band corresponding to γ-γ dimers 
can be seen, along with a decrease in intensity of the γ chain relative to the Bβ chain (Figure 
A.1).  A Western blot of this reaction indicates that this newly appearing band is indeed γ-γ 
(Figure A.2).  These data clearly show that at 1.0 mM CaCl2 factor XIII zymogen was 
capable of cross-linking fibrinogen into γ-γ dimers.  The addition of hirudin to these samples 
does not abrogate cross-link formation, indicating that contamination by thrombin was not 
responsible for this activity (data not shown). 
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Figure A.1 Factor XIII (0.030 mg/mL) and fibrinogen (3.0 mg/mL) incubated with 1.0 mM 
CaCl2 in HBS for the time periods shown, then reduced and run on an 11% gel.  Location of 
γ-γ dimers is marked. 
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Figure A.2 Western blot of fibrinogen + factor XIII zymogen incubation reactions in the 
presence of 1.0 mM CaCl2 as described in the legend to Figure A.1.  The blot was developed 
with NC-15, a γ-chain specific antibody. 
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Cofactor Requirements: Calcium 
To determine whether calcium was a required cofactor for thrombin-independent 
activation, it was omitted from the activation mixture using the assay described above.  
However, the indicator of factor XIII activation in this experiment is cross-linking of 
fibrinogen, a calcium-dependent process.  Figure A.1 shows that 5 minutes was not long 
enough to thrombin independently activate factor XIII and form significant cross-links, but 
control experiments show that activated factor XIIIa can catalyze cross-links in this amount 
of time (data not shown).  Adding calcium back to the reaction mixture for 5 minutes will 
provide a chance for fibrinogen to be cross-linked if factor XIII has already been activated, 
but will not be long enough for measurable new activation of the enzyme.  
Figure A.3 shows the results of this experiment.  Fibrinogen and factor XIII standards 
are shown on the left.  An equimolar mixture of fibrinogen and factor XIII with 1.0 mM 
CaCl2 was incubated for 2 days at room temperature during which factor XIII was thrombin-
independently activated.  Both γ-γ dimers (~90 kDa) and Aα polymers (at the base of sample 
well) formed.  In a mixture of fibrinogen, factor XIII, and 1.0 mM EDTA incubated for 2 
days, neither γ-γ dimers nor Aα polymers formed.  The last lane on the gel shows the same 
incubation mixture with 3.0 mM CaCl2 added during the last five minutes of incubation.  
This concentration of calcium balanced out the effect of the EDTA and returned 1.0 mM 
CaCl2 to the reactants for the 5-minute cross-linking period.  Because no cross-links formed 
between fibrinogen molecules when EDTA was present during activation even when CaCl2 is 
returned during cross-linking, CaCl2 is a required cofactor for thrombin-independent 
activation.  
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Figure A.3.  Calcium is a required cofactor for thrombin-independent factor XIII activation.  
8.8 µM fibrinogen standard and 8.8 µM factor XIII standard are in the first two wells.  For 
the other samples, 8.8 µM each of fibrinogen and factor XIII are incubated for 2 days with 
1.0 mM CaCl2, 1.0 mM EDTA, or 1.0 mM EDTA plus 3.0 mM CaCl2 for the last 5 minutes.  
The locations of γ-γ dimer and Aα-polymer bands are shown. 
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Cofactor Requirements:  Fibrinogen 
 In a system similar to the one described above for evaluating the contribution of 
calcium to thrombin-independent activation of factor XIII, the requirement for fibrinogen as 
a cofactor was also investigated.  Fibrinogen was omitted during the original 2 day factor 
XIII activation period and added back for the 5 minute cross-linking period.  Figure A.4 
shows that under these conditions cross-links did not form; along with calcium, fibrinogen is 
a necessary cofactor for thrombin-independent activation of factor XIII. 
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Figure A.4.  Fibrinogen is a required cofactor for thrombin-independent activation of factor 
XIII.  8.8 µM fibrinogen standard and 8.8 µM factor XIII standard are in the first two wells.  
In the next sample, 8.8 µM each of fibrinogen and factor XIII are incubated for 2 days with 
1.0 mM CaCl2.  The last lane shows 8.8 µM factor XIII + 1.0 mM CaCl2 incubated for 2 days 
with 8.8 µM fibrinogen added back in the last 5 minutes.  The locations of γ-γ dimer and Aα-
polymer bands are shown. 
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 Because fibrinogen is both cofactor and substrate when factor XIII activation is 
measured by cross-linking of fibrinogen, it simplifies analysis to remove its role as substrate 
when attempting to study its cofactor activity.  To do this, I have employed a 
dansylcadaverine incorporation assay, originally described by Lorand [11].  In this assay, 
factor XIII(a) (activated either with or without thrombin, under various conditions) catalyzes 
incorporation of the fluorescent substrate dansylcadaverine into the protein N,N′-
dimethylcasein.  Incorporation into the hydrophobic protein alters the fluorescence intensity 
of the dansylcadaverine and the rate of incorporation can be measured by the slope of 
fluorescence increase, monitored kinetically.  Fibrinogen was included with factor XIII 
zymogen for 2 days prior to the dansylcadaverine incorporation experiment for thrombin-
independent activation.  The concentration of fibrinogen during the activation period was 
0.88 µM, but was diluted to 0.088 µM before the fluorescence monitoring began.  This 
dilution prevented fibrinogen from effectively competing with the 2.5 mM dansylcadaverine 
as a substrate for factor XIII.  As an additional precaution, fibrinogen concentrations were 
equalized in all samples before the start of the fluorescence incorporation reaction, even if 
fibrinogen was not included in the initial activation mixture. DTT was not included during 
the activation period, but was added to the incorporation reaction to increase factor XIII’s 
response to a non-physiological substrate.  Figure A.5 shows how this experiment provides a 
quantitative measure of factor XIII activation under various conditions.  Factor XIII zymogen 
activation in the presence of EDTA gave a slope of dansylcadaverine incorporation that was 
close to zero, similar to the no FXIII control sample.  As the concentration of calcium 
increased, the slope of dansylcadaverine incorporation (measured as fluorescence versus 
time) increased until we reach 50 mM CaCl2 which displayed the same rate of activity as 
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thrombin-activated factor XIIIa.  A straight line at 65,535 fluorescence units indicates 
saturation of the instrument’s sensitivity.  Table A.1 demonstrates the relationship between 
calcium concentration and extent of activation of factor XIII zymogen. 
To determine the need for fibrinogen as cofactor in thrombin-independent activation 
of factor XIII, factor XIII was activated at different concentrations of calcium with and 
without fibrinogen and then used in the dansylcadaverine incorporation assay.  Figure A.6 
shows the results of this experiment.  To account for day-to-day variability of the fluorescent 
substrate, slopes were measured as a percent of the thrombin-activated factor XIIIa activity.  
At 1.0 mM CaCl2, addition of fibrinogen produced a significant increase in the activity of 
factor XIII compared to 1.0 mM CaCl2 in the absence of fibrinogen.  At 5.0 mM CaCl2 this 
effect was abolished.  Fibrinogen also had no effect on activity at 50 mM CaCl2, consistent 
with the observations of Credo and coworkers [1].  Thus, fibrinogen is only necessary at a 
low, physiological concentration of CaCl2 (1 mM) to act as a cofactor in thrombin-
independent activation of factor XIII.  
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Figure A.5.  Dansylcadaverine incorporation assay for thrombin-activated factor XIIIa and 
thrombin-independently activated factor XIII zymogen.  Incorporation of dansylcadaverine 
into N,N′-dimethylcasein by factor XIII is measured as an increase in fluorescence intensity 
over time.  Factor XIII was activated by thrombin (red) or incubation with 0.30 mg/mL 
fibrinogen + the concentration of CaCl2 or EDTA listed in the legend.  Samples lacking 
FXIII (purple) or fluorescent substrate (black) are included as controls. 
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Dansylcadaverine Incorporation by Factor XIII(a) 
Method of FXIII Activation Activity (slope of dansylcadaverine incorporation, s-1) 
0.25 U/mL thrombin 6.0 +/- 1.3 
2.0 mM EDTA 0.23 +/- 0.05 
1.5 mM CaCl2 1.3 +/- 0.2 
5.0 mM CaCl2 1.6 +/- 0.3 
10 mM CaCl2 2.0 +/- 0.3 
50 mM CaCl2 5.4 +/- 1.8 
No FXIII control 0.12 +/- 0.06 
Table A.1.  Activation of factor XIII zymogen is directly related to the concentration of 
calcium with which it is incubated.  Slopes determined from Figure A.5. 
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Figure A.6.  Factor XIII activity generated by thrombin or thrombin-independently with and 
without fibrinogen at 1.0 mM, 5.0 mM, and 50 mM CaCl2 determined by dansylcadaverine 
incorporation.  Experiments were performed as described in Methods.  The asterisk denotes a 
significant increase in activation in the presence of fibrinogen compared to its absence. 
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Catalysis of Thrombin-Independent Factor XIII Activation by Variant Fibrinogens 
 To locate the domain on fibrinogen responsible for catalyzing thrombin-independent 
activation of factor XIII at low concentrations of calcium, we employed recombinant 
fibrinogen variants in the dansylcadaverine incorporation assay.  To see if the presence of the 
γ′ extension played a role in this process, recombinant γ′/γ′ fibrinogen was used.  We 
included Aα251 fibrinogen, in which the Aα-chain is truncated at residue 251, to explore the 
role of the αC domain in activation.  These recombinant fibrinogens were mixed with factor 
XIII zymogen at 0.30 mg/mL, along with 1.0 mM CaCl2, with or without thrombin to 
activate the factor XIII.  As can be seen in Figure A.7, the presence of thrombin increased the 
extent of factor XIII activation, but in its absence factor XIII still displayed significant 
dansylcadaverine incorporation.  Table A.2 reports the slope of incorporation from Figure 
A.7, a measure of factor XIII activity.  While the activity of thrombin-activated factor XIIIa 
was the same no matter which fibrinogen was present during activation, inclusion of both of 
the mutant fibrinogens led to statistically significant lowered activity of thrombin-
independently activated factor XIII compared to normal recombinant fibrinogen.  This 
finding suggested that both the γ′ region and the αC domain play a role in thrombin-
independent factor XIII activation.   
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Figure A.7.  Thrombin-cleaved (open symbols) and thrombin-independently activated 
(closed symbols) factor XIII(a) in dansylcadaverine incorporation assay.  Normal 
recombinant fibrinogen (red), γ′/γ′ fibrinogen (blue), and Aα251 fibrinogen (green) were 
included in the assay.  Experiments were performed as described in Methods with 0.30 
mg/mL factor XIII, 0.30 mg/mL recombinant fibrinogen, and either 1.0 mM CaCl2 or 2.5 
U/mL thrombin. 
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Dansylcadaverine Incorporation for Factor XIII(a) Activated with Recombinant 
Fibrinogens 
Fibrinogen Rate of Incorporation for 
Thrombin-Catalyzed Factor 
XIIIa (slope x 10-5 +/- std dev) 
Rate of Incorporation for 
Thrombin-Independently Activated 
Factor XIII (slope x 10-5 +/- std dev) 
Normal 10 +/- 0.7 2.6 +/- 0.2 
γ′/γ′ 9.0 +/- 0.7 1.7* +/- 0.6 
Aα251 9.6 +/- 0.5 2.1* +/- 0.3 
Table A.2.  The rate of dansylcadaverine incorporation into casein is proportional to the 
extent of factor XIII activation.  The slope of dansylcadaverine incorporation from Figure 
A.7 is reported +/- standard deviation for each activation condition. An asterisk (*) denotes p 
< 0.05, compared to normal recombinant fibrinogen. 
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Visualization of Thrombin-Independent Activation of Factor XIII by Native Gel 
Electrophoresis 
 A native gel was run of factor XIII activated by 10 U/mL thrombin, 50 mM CaCl2 + 
plasma fibrinogen, or 1 mM CaCl2 + plasma fibrinogen.  The subunits of factor XIII remain 
associated on a native gel, allowing us to probe the structure that results from each of these 
activation methods, compared to unactivated factor XIII.  See Figure A.8. 
All three methods of activation used to prepare samples for this gel have generated 
factor XIII capable of cross-linking as shown on reducing gels (see Figures A.1,2).  Cross-
linking of fibrinogen can be seen on this native gel by a loss of intensity in the fibrinogen 
bands.  Factor XIII activated with 1.0 mM CaCl2 cross-linked less of the fibrinogen than 
factor XIII activated by either 50 mM CaCl2 or thrombin, but still showed some dissipation 
of the fibrinogen band compared to the sample treated with EDTA.  Thus, each of these lanes 
contain activated factor XIII.  The A and B subunits remained associated in the samples 
activated with CaCl2, but dissociated in the sample activated by thrombin.  This observation 
suggests a structural difference between the different methods of activation. 
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Figure A.8.  Native 4-15% Tris gel of factor XIII incubated with 2 mM EDTA, 1 mM CaCl2 
+ fibrinogen, 50 mM CaCl2 + fibrinogen, or 10 U/mL IIa + 1 mM CaCl2 + fibrinogen.   
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Discussion 
 The experiments described in this appendix confirm the assertions made by 
Siebenlist, Meh, and Mosesson in 2001 that factor XIII zymogen can become active and 
cross-link fibrinogen, without activation peptide cleavage by thrombin [6].  We have shown 
that γ-γ and Aα cross-links formed within one hour at physiological concentrations of 
fibrinogen, factor XIII, and calcium in the absence of thrombin (Figures A.1, 2).  We have 
also shown that this thrombin-independent activation was dependent on the presence of 
calcium (Figure A.3) and the extent of activation was directly proportional to the 
concentration of calcium present during the activation period (Figure A.5).   
 Dansylcadaverine incorporation experiments have been used to demonstrate that at 
low, physiological concentrations of calcium, fibrinogen was a required cofactor for 
thrombin-independent factor XIII activation (Figure A.6).  Various regions of the fibrinogen 
molecule have been implicated in this cofactor activity, as shown by the use of γ′/γ′ and 
Aα251 recombinant fibrinogens as cofactor in thrombin-independent factor XIII activation 
(Figure A.7).  While the presence of γ′ chains inhibited this activation process, the αC-
domain was necessary for it to take place to its full extent.  Notably, however, inclusion of 
neither mutant in the preactivation period completely abrogated activation of factor XIII 
zymogen, suggesting that factor XIII may interact with multiple domains of fibrinogen 
during thrombin-independent activation. 
Finally, a native gel showed that while thrombin-catalyzed activation of factor XIII 
led to subunit dissociation, thrombin-independent activation took place with the subunits 
remaining associated as A2B2 (Figure A.8).  This conformational difference suggests that 
factor XIII activated in these two different ways is a completely different molecule; it is 
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therefore all the more remarkable that factor XIII activated by 50 mM CaCl2 generates the 
same level of activity as factor XIII activated by 0.25 U/mL thrombin (Table A.1). 
 Thrombin-independent activation of factor XIII in the blood could potentially lead to 
catastrophic thrombotic effects.  From the experiments described here, I cannot comment as 
to whether the activity I have characterized leads to a small amount of cross-linked 
fibrinogen molecules that circulate in the blood as suggested by Siebenlist et al [6], or if it is 
simply an in vitro effect as suggested by Shainoff and DiBello [7].  What is clear, however, is 
that this activity affects any experiments in which fibrinogen and factor XIII are mixed in the 
presence of calcium for more than just a few moments.  Use of the lowest possible 
concentrations of calcium will minimize this effect.  Some recombinant fibrinogen variants 
will catalyze less activation than others.  But some conversion of factor XIII into an active 
form will necessarily take place in each experiment.  I used this background to design 
experiments and interpret data from them in the most informed manner. 
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